US20190345636A1 - Methods and systems for molecular library generation - Google Patents

Abstract

The present disclosure provides methods and systems for generation of libraries comprising two or more sets of molecules. Libraries may comprise sets of molecules of different types. Sets of molecules may be generated by attachment to supports. Different types of molecules may be generated combinatorially, thereby generating a large number of unique molecules. One or more types of molecules may be used to identify one or more additional types of molecules. Libraries of the present disclosure may be used in, for example, nucleic acid sequencing.

Description

CROSS-REFERENCE
• This application is a continuation of PCT Application Serial No. PCT/US2019/031629, filed May 9, 2019, which claims priority to U.S. Provisional Patent Application No. 62/669,796, filed May 10, 2018, and U.S. Provisional Patent Application No. 62/681,612, filed Jun. 6, 2018, each of which is entirely incorporated herein by reference for all purposes.
BACKGROUND
• A sample may be processed for various purposes, such as identification of a type of moiety within the sample. The sample may be a biological sample. Biological samples may be processed, such as for detection of a disease (e.g., cancer) or identification of a particular species. There are various approaches for processing samples, such as polymerase chain reaction (PCR) and sequencing.
• Biological samples may be processed within various reaction environments, such as partitions. Partitions may be wells or droplets. Droplets or wells may be employed to process biological samples in a manner that enables the biological samples to be partitioned and processed separately. For example, such droplets may be fluidically isolated from other droplets, enabling accurate control of respective environments in the droplets.
• Biological samples in partitions may be subjected to various processes, such as chemical processes or physical processes. Samples in partitions may be subjected to heating or cooling, or chemical reactions, such as to yield species that may be qualitatively or quantitatively processed.
SUMMARY
• Generation of large sets of molecules can be useful in various applications, including nucleic acid sequencing. A set of molecules may be generated combinatorially, which may comprise the addition of one or more molecules in successive operations. A set of molecules may be attached to or comprised in a support (e.g., a bead). Combinatorial generation may be used to generate a large set of molecules of a single type, such as nucleic acid molecules (e.g., DNA, RNA, etc.). Recognized herein is a need for systems and methods that enable the effective generation of libraries of two or more sets of molecules of different types. One type of molecule may be used to positively identify another type of molecule, which may be useful in characterizing one or more components of a sample (e.g., a cell).
• Disclosed herein, in some embodiments, is a method for generating a plurality of molecules, comprising: (a) providing a plurality of supports; and (b) combinatorially generating a plurality of molecules coupled to and/or comprised in each of the plurality of supports, wherein a support of the plurality of supports comprises a first set of molecules and a second set of molecules of the plurality of molecules, which first set of molecules and second set of molecules are of different types. In some embodiments, the first set of molecules includes deoxyribonucleic acid molecules and the second set of molecules includes ribonucleic acid molecules. In some embodiments, the first set of molecules includes deoxyribonucleic acid molecules and the second set of molecules includes peptide molecules. In some embodiments, the first set of molecules includes ribonucleic acid molecules and the second set of molecules includes peptide molecules. In some embodiments, the first set of molecules includes deoxyribonucleic acid molecules and the second set of molecules includes chemical compounds each having a molecular weight less than 900 Daltons. In some embodiments, the first set of molecules includes ribonucleic acid molecules and the second set of molecules includes chemical compounds each having a molecular weight less than 900 Daltons. In some embodiments, the first set of molecules includes deoxyribonucleic acid (DNA) molecules and/or ribonucleic acid (RNA) molecules, and the second set of molecules includes molecules that are not DNA and RNA. In some embodiments, the first set of molecules comprises one or more nucleic acid barcode sequences.
• In some embodiments, the plurality of supports is a plurality of beads. In some embodiments, molecules of the first set of molecules have sequences that encode molecules of the second set of molecules. In some embodiments, the first set of molecules positively identifies the second set of molecules. In some embodiments, at least a subset of the plurality of molecules is generated by sequentially coupling one or more molecules to the plurality of supports. In some embodiments, the at least the subset of the plurality of molecules comprises a first molecule comprising a first segment and a second molecule comprising a second segment, and wherein the combinatorially generating comprises coupling the first molecule to a molecule coupled to a support of the plurality of supports and coupling the second molecule to the first molecule. In some embodiments, the second segment is different from the first segment. In some embodiments, the first segment and the second segment are nucleic acid segments. In some embodiments, the first segment and the second segment are at least one nucleotide in length.
• In some embodiments, the method further comprises coupling a third molecule comprising a third segment to the second molecule. In some embodiments, the third segment is different from the first segment or the second segment. In some embodiments, the third segment is different from the first segment and the second segment. In some embodiments, the third segment is a nucleic acid segment. In some embodiments, the third segment is at least one nucleotide in length. In some embodiments, the coupling comprises partitioning the at least the subset of the plurality of molecules in separate partitions, and coupling the one or more molecules to each of the plurality of supports in the separate partitions. In some embodiments, the partitions are wells. In some embodiments, the partitions are droplets.
• In some embodiments, at least a subset of the plurality of molecules are generated by sequentially capturing one or more molecules within the plurality of supports. In some embodiments, the plurality of supports is a plurality of beads, and wherein the capturing comprises encapsulating the one or more molecules in the plurality of beads. In some embodiments, the capturing comprises partitioning the at least the subset of the plurality of molecules in separate partitions, and capturing the one or more molecules in each of the plurality of supports in the separate partitions. In some embodiments, the partitions are wells. In some embodiments, the partitions are droplets
• Disclosed herein, in some embodiments, is a method for generating a plurality of molecules, comprising: (a) providing a plurality of supports in a first plurality of partitions comprising a first set of molecules and a second set of molecules, which first set of molecules and second set of molecules are of different types; (b) coupling said first set of molecules and said second set of molecules to said plurality of supports; (c) providing said plurality of supports in a second plurality of partitions comprising a third set of molecules and a fourth set of molecules which third set of molecules and fourth set of molecules are of different types; and (d) coupling said third set of molecules and said fourth set of molecules to said plurality of supports. In some embodiments, (i) said first set of molecules and said third set of molecules comprise deoxyribonucleic acid molecules and (ii) said second set of molecules and said fourth set of molecules comprise ribonucleic acid molecules. In some embodiments, (i) said first set of molecules and said third set of molecules comprise deoxyribonucleic acid molecules and (ii) said second set of molecules and said fourth set of molecules comprise polypeptide molecules. In some embodiments, (i) said first set of molecules and said third set of molecules comprise ribonucleic acid molecules and (ii) said second set of molecules and said fourth set of molecules comprise polypeptide molecules. In some embodiments, (i) said first set of molecules and said third set of molecules comprise deoxyribonucleic acid molecules and (ii) said second set of molecules and said fourth set of molecules comprise chemical compounds each having a molecular weight less than 900 Daltons. In some embodiments, (i) said first set of molecules and said third set of molecules comprise ribonucleic acid molecules and (ii) said second set of molecules and said fourth set of molecules comprise chemical compounds each having a molecular weight less than 900 Daltons. In some embodiments, (i) said first set of molecules and said third set of molecules comprise deoxyribonucleic acid (DNA) molecules and/or ribonucleic acid (RNA) molecules, and (ii) said second set of molecules and said fourth set of molecules comprise molecules that are not DNA and RNA. In some embodiments, (d) comprises coupling said third set of molecules to said first set of molecules. In some embodiments, (d) comprises coupling said third set of molecules directly to said plurality of supports. In some embodiments, (d) comprises coupling said fourth set of molecules to said second set of molecules. In some embodiments, (d) comprises coupling said fourth set of molecules directly to said plurality of supports. In some embodiments, said first set of molecules and/or said third set of molecules comprises one or more nucleic acid barcode sequences.
• In some embodiments, said plurality of supports is a plurality of beads. In some embodiments, said first set of molecules and said third set of molecules positively identify said second set of molecules and said fourth set of molecules. In some embodiments, the method further comprises (e) providing said plurality of supports in a third plurality of partitions comprising a fifth set of molecules and a sixth set of molecules which fifth set of molecules and sixth second set of molecules are of different types. In some embodiments, the method further comprises (f) coupling said fifth set of molecules and said sixth set of molecules to said plurality of supports. In some embodiments, said first plurality of partitions is a plurality of wells. In some embodiments, said first plurality of partitions is a plurality of droplets. In some embodiments, said second plurality of partitions is a plurality of wells. In some embodiments, said first plurality of partitions is a plurality of droplets. In some embodiments, a partition of said first plurality of partitions comprises a subset of molecules of said first set of molecules, wherein said subset of molecules are identical to one another. In some embodiments, molecules of said subset of molecules are different from molecules of other subsets of molecules in other partitions of said first plurality of partitions. In some embodiments, a partition of said second plurality of partitions comprises a subset of molecules of said second set of molecules, wherein said subset of molecules are identical to one another. In some embodiments, molecules of said subset of molecules are different from molecules of other subsets of molecules in other partitions of said second plurality of partitions.
• Another aspect of the present disclosure provides a non-transitory computer readable medium comprising machine executable code that, upon execution by one or more computer processors, implements any of the methods above or elsewhere herein.
• Another aspect of the present disclosure provides a system comprising one or more computer processors and computer memory coupled thereto. The computer memory comprises machine executable code that, upon execution by the one or more computer processors, implements any of the methods above or elsewhere herein.
• Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.
INCORPORATION BY REFERENCE
• All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.
BRIEF DESCRIPTION OF THE DRAWINGS
• The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also “Figure” and “FIG.” herein), of which:
• FIG. 1 shows an example of a microfluidic channel structure for partitioning individual biological particles.
• FIG. 2 shows an example of a microfluidic channel structure for delivering barcode carrying beads to droplets.
• FIG. 3 shows an example of a microfluidic channel structure for co-partitioning biological particles and reagents.
• FIG. 4 shows an example of a microfluidic channel structure for the controlled partitioning of beads into discrete droplets.
• FIG. 5 shows an example of a microfluidic channel structure for increased droplet generation throughput.
• FIG. 6 shows another example of a microfluidic channel structure for increased droplet generation throughput.
• FIG. 7A shows a cross-section view of another example of a microfluidic channel structure with a geometric feature for controlled partitioning.FIG. 7B shows a perspective view of the channel structure ofFIG. 7A.
• FIG. 8 illustrates an example of a barcode carrying bead.
• FIG. 9 illustrates an example process for combinatorially generating a library of two sets of different types of molecules coupled to beads.
• FIG. 10 illustrates an example process for combinatorially generating a set of nucleic acid molecules coupled to beads and a set of chemical compound combinations comprised in beads.
• FIG. 11 shows an example process for screening for B-cell receptor specificity using a library comprising a set of peptide molecules and a set of nucleic acid barcode molecules, each coupled to beads.
• FIGS. 12A-12D illustrate example methods for attaching a polypeptide to a bead.FIG. 12A shows the use of a histidine tag to attach a polypeptide to a bead.FIG. 12B shows the use of a streptavidin-biotin linkage to attach a polypeptide to a bead.FIG. 12C shows the use of an aptamer to attach a polypeptide to a bead.FIG. 12D shows the use of an antibody or antibody fragment to attach a polypeptide to a bead.
• FIG. 13 illustrates an example process for combinatorially generating a set of nucleic acid molecules and a set of highly functionalized nucleic acid polymers each coupled to a bead.
• FIG. 14 shows a computer system that is programmed or otherwise configured to implement methods provided herein.
DETAILED DESCRIPTION
• While various embodiments of the invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed.
• Where values are described as ranges, it will be understood that such disclosure includes the disclosure of all possible sub-ranges within such ranges, as well as specific numerical values that fall within such ranges irrespective of whether a specific numerical value or specific sub-range is expressly stated.
• The term “barcode,” as used herein, generally refers to a label, or identifier, that conveys or is capable of conveying information about an analyte. A barcode can be part of an analyte. A barcode can be independent of an analyte. A barcode can be a tag attached to an analyte (e.g., nucleic acid molecule) or a combination of the tag in addition to an endogenous characteristic of the analyte (e.g., size of the analyte or end sequence(s)). A barcode may be unique. Barcodes can have a variety of different formats. For example, barcodes can include: polynucleotide barcodes; random nucleic acid and/or amino acid sequences; and synthetic nucleic acid and/or amino acid sequences. A barcode can be attached to an analyte in a reversible or irreversible manner. A barcode can be added to, for example, a fragment of a deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sample before, during, and/or after sequencing of the sample. Barcodes can allow for identification and/or quantification of individual sequencing-reads.
• The term “real time,” as used herein, can refer to a response time of less than about 1 second, a tenth of a second, a hundredth of a second, a millisecond, or less. The response time may be greater than 1 second. In some instances, real time can refer to simultaneous or substantially simultaneous processing, detection or identification.
• The term “subject,” as used herein, generally refers to an animal, such as a mammal (e.g., human) or avian (e.g., bird), or other organism, such as a plant. For example, the subject can be a vertebrate, a mammal, a rodent (e.g., a mouse), a primate, a simian or a human. Animals may include, but are not limited to, farm animals, sport animals, and pets. A subject can be a healthy or asymptomatic individual, an individual that has or is suspected of having a disease (e.g., cancer) or a pre-disposition to the disease, and/or an individual that is in need of therapy or suspected of needing therapy. A subject can be a patient. A subject can be a microorganism or microbe (e.g., bacteria, fungi, archaea, viruses).
• The term “genome,” as used herein, generally refers to genomic information from a subject, which may be, for example, at least a portion or an entirety of a subject's hereditary information. A genome can be encoded either in DNA or in RNA. A genome can comprise coding regions (e.g., that code for proteins) as well as non-coding regions. A genome can include the sequence of all chromosomes together in an organism. For example, the human genome ordinarily has a total of 46 chromosomes. The sequence of all of these together may constitute a human genome.
• The terms “adaptor(s)”, “adapter(s),” and “tag(s)” may be used synonymously. An adaptor or tag can be coupled to a polynucleotide sequence to be “tagged” by any approach, including ligation, hybridization, or other approaches.
• The term “sequencing,” as used herein, generally refers to methods and technologies for determining the sequence of nucleotide bases in one or more polynucleotides. The polynucleotides can be, for example, nucleic acid molecules such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), including variants or derivatives thereof (e.g., single stranded DNA). Sequencing can be performed by various systems currently available, such as, without limitation, a sequencing system by Illumina®, Pacific Biosciences (PacBio®), Oxford Nanopore®, or Life Technologies (Ion Torrent®). Alternatively or in addition, sequencing may be performed using nucleic acid amplification, polymerase chain reaction (PCR) (e.g., digital PCR, quantitative PCR, or real time PCR), or isothermal amplification. Such systems may provide a plurality of raw genetic data corresponding to the genetic information of a subject (e.g., human), as generated by the systems from a sample provided by the subject. In some examples, such systems provide sequencing reads (also “reads” herein). A read may include a string of nucleic acid bases corresponding to a sequence of a nucleic acid molecule that has been sequenced. In some situations, systems and methods provided herein may be used with proteomic information.
• The term “bead,” as used herein, generally refers to a particle. The bead may be a solid or semi-solid particle. The bead may be a gel bead. The gel bead may include a polymer matrix (e.g., matrix formed by polymerization or cross-linking). The polymer matrix may include one or more polymers (e.g., polymers having different functional groups or repeat units). Polymers in the polymer matrix may be randomly arranged, such as in random copolymers, and/or have ordered structures, such as in block copolymers. Cross-linking can be via covalent, ionic, or inductive, interactions, or physical entanglement. The bead may be a macromolecule. The bead may be formed of nucleic acid molecules bound together. The bead may be formed via covalent or non-covalent assembly of molecules (e.g., macromolecules), such as monomers or polymers. Such polymers or monomers may be natural or synthetic. Such polymers or monomers may be or include, for example, nucleic acid molecules (e.g., DNA or RNA). The bead may be formed of a polymeric material. The bead may be magnetic or non-magnetic. The bead may be rigid. The bead may be flexible and/or compressible. The bead may be disruptable or dissolvable. The bead may be a solid particle (e.g., a metal-based particle including but not limited to iron oxide, gold or silver) covered with a coating comprising one or more polymers. Such coating may be disruptable or dissolvable.
• The term “sample,” as used herein, generally refers to a biological sample of a subject. The biological sample may comprise any number of macromolecules, for example, cellular macromolecules. The sample may be a cell sample. The sample may be a cell line or cell culture sample. The sample can include one or more cells. The sample can include one or more microbes. The biological sample may be a nucleic acid sample or protein sample. The biological sample may also be a carbohydrate sample or a lipid sample. The biological sample may be derived from another sample. The sample may be a tissue sample, such as a biopsy, core biopsy, needle aspirate, or fine needle aspirate. The sample may be a fluid sample, such as a blood sample, urine sample, or saliva sample. The sample may be a skin sample. The sample may be a cheek swab. The sample may be a plasma or serum sample. The sample may be a cell-free or cell free sample. A cell-free sample may include extracellular polynucleotides. Extracellular polynucleotides may be isolated from a bodily sample that may be selected from the group consisting of blood, plasma, serum, urine, saliva, mucosal excretions, sputum, stool and tears.
• The term “biological particle,” as used herein, generally refers to a discrete biological system derived from a biological sample. The biological particle may be a macromolecule. The biological particle may be a small molecule. The biological particle may be a virus. The biological particle may be a cell or derivative of a cell. The biological particle may be an organelle. The biological particle may be a rare cell from a population of cells. The biological particle may be any type of cell, including without limitation prokaryotic cells, eukaryotic cells, bacterial, fungal, plant, mammalian, or other animal cell type, mycoplasmas, normal tissue cells, tumor cells, or any other cell type, whether derived from single cell or multicellular organisms. The biological particle may be a constituent of a cell. The biological particle may be or may include DNA, RNA, organelles, proteins, or any combination thereof. The biological particle may be or may include a matrix (e.g., a gel or polymer matrix) comprising a cell or one or more constituents from a cell (e.g., cell bead), such as DNA, RNA, organelles, proteins, or any combination thereof, from the cell. The biological particle may be obtained from a tissue of a subject. The biological particle may be a hardened cell. Such hardened cell may or may not include a cell wall or cell membrane. The biological particle may include one or more constituents of a cell, but may not include other constituents of the cell. An example of such constituents is a nucleus or an organelle. A cell may be a live cell. The live cell may be capable of being cultured, for example, being cultured when enclosed in a gel or polymer matrix, or cultured when comprising a gel or polymer matrix.
• The term “macromolecular constituent,” as used herein, generally refers to a macromolecule contained within or from a biological particle. The macromolecular constituent may comprise a nucleic acid. In some cases, the biological particle may be a macromolecule. The macromolecular constituent may comprise DNA. The macromolecular constituent may comprise RNA. The RNA may be coding or non-coding. The RNA may be messenger RNA (mRNA), ribosomal RNA (rRNA) or transfer RNA (tRNA), for example. The RNA may be a transcript. The RNA may be small RNA that are less than 200 nucleic acid bases in length, or large RNA that are greater than 200 nucleic acid bases in length. Small RNAs may include 5.8S ribosomal RNA (rRNA), 5S rRNA, transfer RNA (tRNA), microRNA (miRNA), small interfering RNA (siRNA), small nucleolar RNA (snoRNAs), Piwi-interacting RNA (piRNA), tRNA-derived small RNA (tsRNA) and small rDNA-derived RNA (srRNA). The RNA may be double-stranded RNA or single-stranded RNA. The RNA may be circular RNA. The macromolecular constituent may comprise a protein. The macromolecular constituent may comprise a peptide. The macromolecular constituent may comprise a polypeptide.
• The term “molecular tag,” as used herein, generally refers to a molecule capable of binding to a macromolecular constituent. The molecular tag may bind to the macromolecular constituent with high affinity. The molecular tag may bind to the macromolecular constituent with high specificity. The molecular tag may comprise a nucleotide sequence. The molecular tag may comprise a nucleic acid sequence. The nucleic acid sequence may be at least a portion or an entirety of the molecular tag. The molecular tag may be a nucleic acid molecule or may be part of a nucleic acid molecule. The molecular tag may be an oligonucleotide or a polypeptide. The molecular tag may comprise a DNA aptamer. The molecular tag may be or comprise a primer. The molecular tag may be, or comprise, a protein. The molecular tag may comprise a polypeptide. The molecular tag may be a barcode.
• The term “partition,” as used herein, generally, refers to a space or volume that may be suitable to contain one or more species or conduct one or more reactions. A partition may be a physical compartment, such as a droplet or well. The partition may isolate space or volume from another space or volume. The droplet may be a first phase (e.g., aqueous phase) in a second phase (e.g., oil) immiscible with the first phase. The droplet may be a first phase in a second phase that does not phase separate from the first phase, such as, for example, a capsule or liposome in an aqueous phase. A partition may comprise one or more other (inner) partitions. In some cases, a partition may be a virtual compartment that can be defined and identified by an index (e.g., indexed libraries) across multiple and/or remote physical compartments. For example, a physical compartment may comprise a plurality of virtual compartments.
• Provided herein are methods, systems, and compositions for the generation of libraries comprising two or more sets of molecules of different types. In some cases, sets of molecules are generated combinatorially, thereby generating a diverse library of molecules. A set of molecules may be a set of nucleic acid molecules, a set of peptide molecules, a set of chemical compounds (e.g., compounds less than 1000 Daltons, 900 Daltons, 800 Daltons, 700 Daltons, 600 Daltons, 500 Daltons, or less), or any other type of molecule. A set of chemical compounds may be a set of compound combinations (e.g., drug combinations). Sets of molecules may be attached to supports (e.g., beads). Sets of molecules may be captured in supports (e.g. beads).
• In some cases, supports (e.g. beads, for instance, gel beads) are partitioned into a first plurality of wells comprising two or more different types of molecules. Supports may be functionalized with one or more moieties for attachment of one or more molecules. Each well of a plurality of wells may comprise one or more segments of two or more different types of molecules. A segment may be, for example, a nucleic acid segment (e.g., deoxyribonucleic acid, ribonucleic acid, etc.), or a polypeptide segment. Segments may be different across wells. Alternatively or in addition, each well may comprise chemical compounds (e.g., compounds less than 900 Daltons). Chemical compounds may be different across wells. Molecules may be arranged in the plurality of wells such that the contents of each well are known, and can be linked to one another. For example, a given well can have a known nucleic acid segment and also a known polypeptide segment.
• Following partitioning, molecules in the wells may be attached to and/or captured in the supports. In one example, a first deoxyribonucleic acid (DNA) segment can be attached to supports in a well and a first polypeptide segment can be attached to the same supports in the same well. In another example, a first DNA segment can be attached to the supports in a well and a first chemical compound (e.g., a first drug) can be captured in the same supports in the same well. In a third example, a first DNA segment can be attached to supports in a well and a first RNA segment can be attached to the same supports in the same well. Supports can be removed from the first set of wells and pooled. The pooled supports can be partitioned into a second plurality of wells comprising two or more different types of molecules. Molecules in the wells can be attached to and/or captured in the supports as before. In one example, a second DNA segment can be attached to a first DNA segment attached to supports in a well and a second polypeptide segment can be attached to a first polypeptide segment attached to the same supports in the same well. In another example, a second DNA segment can be attached to a first DNA segment attached to supports in a well and a second chemical compound (e.g., a second drug) can be captured together with a first chemical compound in the same supports in the same well. In a third example, a second DNA segment can be attached to a first DNA segment attached to supports in a well and a second RNA segment can be attached to a first RNA segment attached to the same supports in the same well. Supports can be removed from the second set of wells and pooled, thereby generating a population of supports that are each associated with two or more different types of combinatorially synthesized molecules, thereby generating a library comprising two or more sets of molecules.
• A library comprising two or more sets of molecules of different types may allow the use of one or more types of molecules to identify one or more molecules of another type. For example, a nucleic acid molecule comprising a unique barcode sequence can be attached to a support. In one example, the unique barcode sequence can be used to individually identify a polypeptide sequence attached to the same support. Identification of a polypeptide sequence from a nucleic acid barcode sequence may be useful in, for example, identifying both nucleic acid sequence information from a single cell and also the specificity of a protein (e.g., a receptor) from that cell for a given polypeptide sequence. In another example, the unique barcode sequence may be used to identify a compound combination (e.g., drug combination) comprised in the support. Identification of a compound combination from a nucleic acid barcode sequence may be useful in, for example, identifying both nucleic acid sequence information from a single cell and also the identity of a compound combination (e.g., a drug combination) applied to the cell. In a further example, the unique barcode sequence may be used to individually identify an RNA sequence attached to the same support. Identification of an RNA sequence from a nucleic acid barcode sequence may be useful in, for example, identifying nucleic acid sequence information from a single cell and also the specificity of a protein (e.g. a receptor) from that cell for a polypeptide sequence derived from the RNA sequence.
• In some cases, multiple nucleic acid molecules comprising different barcode sequences can be attached to a support as a part of a library of the present disclosure. For example, two nucleic acid molecules, each comprising a different barcode sequence, can be attached to a support. A first nucleic acid molecule comprising a first barcode sequence can be used to identify a first type of molecule (e.g. a polypeptide molecule) attached to or comprised in the same support. A second nucleic acid molecule comprising a second barcode sequence can be used to identify a second type of molecule (e.g. a compound combination, such as a drug combination) attached to or comprised in the same support.
Combinatorial Generation of Sets of Molecules
• In some aspects, the present disclosure provides methods and systems for combinatorial generation of sets of molecules. Sets of molecules may be generated by the addition of one or more individual components in successive operations (i.e., may be combinatorial). Successive operations may be performed in separate partitions (e.g., a droplet in an emulsion, a well), or may be performed in the same partition. Sets of molecules may be attached to or comprised in supports. A support may be a bead (e.g., a gel bead), as described herein. Supports may be separated into separate partitions (e.g. wells), pooled, and separated again. In some cases, one or more segments (e.g., nucleic acid segments, polypeptide segments, etc.) can be attached to the supports in each partition, thereby generating a set of molecules (e.g., nucleic acid molecules, polypeptide molecules) each comprising one or more segments. In some cases, one or more chemical compounds (e.g., one or more drugs) can be attached to or comprised in the supports in each partition, thereby generating a set of compound combinations. Each partition may comprise one or more types of molecules. In some cases, each partition comprises 1, 2, 3, 4, 5, or more types of molecules. Combinatorial methods may be useful in, for example, generating large numbers of unique molecules.
• Combinatorial methods may include at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, or more rounds of contacting precursor molecules with reagents to alter characteristics of the precursor molecules, such as generating a greater number of the precursor molecules, increasing a concentration of the precursor molecules, or altering a size and/or sequence of the precursor molecules (e.g., generating larger molecules from the precursor molecules). This may include split-pool approaches in which the precursor molecules are partitioned and pooled one or more times. Precursor molecules in different partitions may be contacted with different reagents. Alternatively, the precursor molecules may be partitioned and brought in contact with different reagents (e.g., the precursor molecules may be immobilized on supports in partitions and brought in contact with different reagents across a plurality of rounds).
• Combinatorial methods may be used to generate a library comprising two or more sets of molecules of different types. Multiple sets of molecules may be attached to a support. A library may be generated in such a way that one or more types of molecules attached to or comprised in a support may be used to identify one or more other types of molecules attached to or comprised in the same support. Supports may be separated into a plurality of partitions. A plurality of partitions may be a plurality of wells. A plurality of partitions may comprise at least 2, 6, 12, 24, 48, 96, 384, 1536, 2080 or more partitions. A plurality of partitions may comprise at most 2080, 1536, 384, 96, 48, 24, 12, 6, or 2 partitions. A partition of a plurality of partitions may comprise one or more different types of molecules (e.g., DNA molecules, RNA molecules, polypeptide molecules, chemical compounds, etc.). Each molecule of a type of molecules within a partition may be identical. For example, a partition may comprise DNA molecules and RNA molecules, where each DNA molecule is identical and each RNA molecule is identical. Molecules within a given partition may be different from those within the other partitions of a plurality of partitions. Partitions may comprise reagents for altering the characteristics of a molecule (e.g., a precursor molecule), such as, for example, reagents for attaching a molecule to a support (e.g., reagents for ligation, reagents for hybridization, etc.). Supports may be partitioned such that at least 1; 2; 3; 4; 5; 10; 20; 50; 100; 500; 1,000; 5,000; 10,000; 100,000; 1,000,000; or more supports are present in a single partition. Supports may be partitioned such that at most 1,000,000; 100,000; 10,000; 5,000; 1,000; 500; 100; 50; 20; 10; 5; 4; 3; 2; or 1 support is present in a single partition. Supports may be partitioned at a random configuration.
• Supports may be partitioned into a plurality of partitions, where each partition comprises two or more types of molecules. Supports may be subjected to conditions sufficient to attach molecules in each well to the supports. Supports may be subjected to conditions sufficient to capture molecules in each well within the supports. Following the attachment and/or capture of molecules, supports may be released from the partitions and, in some cases, pooled. Once pooled, supports may be separated into an additional plurality of partitions. An additional plurality of partitions may be a different plurality of partitions, or may be the same plurality of partitions. Supports may be separated at a random configuration. Supports may be separated at a configuration that is distinct from a previous configuration. Supports can again be subjected to conditions sufficient to attach and/or capture molecules (e.g., different types of molecules) in the partitions, thereby combinatorially generating sets of molecules attached to or comprised in the supports. In some cases, molecules in an additional plurality of partitions can be attached to the supports directly. In some cases, molecules in an additional plurality of partitions can be attached to molecules attached to the supports. Supports can be released from the additional plurality of partitions and, in some cases, pooled. Additional operations comprising separation, attachment or capture, release, and pooling may be performed in the process of combinatorial generation of sets of molecules. Combinatorial methods as described herein may comprise at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, or more operations. Combinatorial methods comprising multiple operations may be useful, for example, in generation of greater library diversity.
• FIG. 9 illustrates an example method for combinatorially generating two sets of different types of molecules coupled to a bead.Beads920 and930 each comprise two attachment moieties,902 and903.Beads920 and930 are each partitioned into individual wells ofplate950. Each well ofplate950 comprises a plurality of DNA segments comprising a barcode sequence. Each well ofplate950 also comprises a plurality of RNA segments. The DNA segments and RNA segments are distributed in the wells in a known configuration. The DNA segments within a single well are identical, and the RNA segments within a single well are identical. Within each well, beads are subjected to conditions sufficient for attachment of the DNA molecules and the RNA molecules to the beads. Following attachment,bead920 comprisesDNA segments904 andRNA segments905, whilebead930 comprisesDNA segments906 andRNA segments907. The beads are removed from the wells and each partitioned into individual wells ofplate960. Each well ofplate960 comprises a plurality of DNA segments comprising a barcode sequence. Each well ofplate960 also comprises a plurality of RNA segments. The DNA segments and RNA segments are distributed in the wells in a known configuration. The DNA segments within a single well are identical, and the RNA segments within a single well are identical. Within each well, beads are subjected to conditions sufficient for attachment of the DNA molecules and the RNA molecules to the previously attached DNA molecules and RNA molecules, respectively. Following attachment,bead920 now comprisesDNA segments908 attached toDNA segments904, making upunique DNA molecules913 comprising a unique barcode sequence.Bead920 also comprisesRNA segments909 attached toRNA segments905, making upunique RNA molecules912. Following attachment,bead930 now comprisesDNA segments910 attached toDNA segments906, making upunique DNA molecules915 comprising a unique barcode sequence.Bead930 also comprisesRNA segments911 attached toRNA segments907, making upunique RNA molecules914. Theunique DNA molecules913 can be used to identify theunique RNA molecules912, and theunique DNA molecules915 can be used to identify theunique RNA molecules914. This can be done, for example, by obtaining sequences of the unique barcode sequences and correlating the sequences with the RNA molecules based on the known configuration of molecules inplates950 and960.
• FIG. 10 illustrates an example method for combinatorially generating a first set of nucleic acid molecules coupled to beads and a second set of molecules comprised in a bead.Beads1020 and1030 each comprise anattachment moiety1001. Beads are also functionalized with amine groups.Beads1020 and1030 are each partitioned into individual wells ofplate1050. Each well ofplate1050 comprises a plurality of DNA segments comprising a barcode sequence. Each well ofplate1050 also comprises a plurality of chemical compounds. The DNA segments and chemical compounds are distributed in the wells in a known configuration. The DNA segments within a single well are identical, and each compound of the plurality of chemical compounds in a single well is identical. Within each well, beads are subjected to conditions sufficient for attachment of the DNA molecules to the beads. Beads are also subjected to conditions sufficient for attachment of the chemical compounds to the gel beads via reaction of a carboxylate group on a compound with an amine group on the bead, thereby forming an amide bond between a compound and a bead. Following this,bead1020 comprisesDNA segments1002 andchemical compounds1003, whilebead1030 comprisesDNA segments1004 andchemical compounds1005. The beads are removed from the wells and each partitioned into individual wells ofplate1060. Each well ofplate1060 comprises a plurality of DNA segments comprising a barcode sequence. Each well ofplate1060 also comprises a plurality of chemical compounds. The DNA segments and chemical compounds are distributed in the wells in a known configuration. The DNA segments within a single well are identical, and each compound of the plurality of chemical compounds in a single well is identical. Compounds across the wells ofplate1060 are different. Within each well, beads are subjected to conditions sufficient for attachment of the DNA molecules to the beads. Beads are also subjected to conditions sufficient for attachment of the chemical compounds to the beads. Following this,bead1020 now comprisesDNA segments1006 attached toDNA segments1002, making upunique DNA segments1010 comprising a unique barcode sequence.Bead1020 also comprises a unique combination ofchemical compounds1007 and1003. Bead1040 now comprisesDNA segments1008 attached toDNA segments1004, making upunique DNA molecules1011 comprising a unique barcode sequence. Bead1040 also comprises a unique combination ofchemical compounds1009 and1005. Theunique DNA molecules1010 can be used to identify the unique combination ofmolecules1003 and1007, and theunique DNA molecules1011 can be used to identify the unique combination ofmolecules1005 and1009. This can be done, for example, by obtaining sequences of the unique barcode sequences and correlating the sequences with the combination of molecules based on the known configuration of molecules inplates1050 and1060.
• FIG. 13 illustrates an example process for combinatorially generating a set of nucleic acid molecules and a set of highly functionalized nucleic acid polymers each coupled to a bead.Bead1320 comprises two moieties attached to firstnucleic acid segments1300 and1302. Combinatorial methods are used to generatenucleic acid molecules1302 and1303 each comprising three nucleic acid segments. 5′ phosphorylated trinucleotides1310,1311, and1312 are provided to the gel bead and attached tonucleic acid molecule1303 to generate highlyfunctionalized nucleotide polymer1304.
Molecules
• Sets of molecules can comprise molecules of a single type. A type of molecule may describe molecules that share chemical and/or physical characteristics. A type of molecule may be a polymer (e.g., synthetic polymer, organic polymer, inorganic polymer, etc.). A type of molecule may be deoxyribonucleic acid (DNA). A type of molecule may be ribonucleic acid (RNA). A type of molecule may be a DNA/RNA hybrid. A type of molecule may be a lipid. A type of molecule may be a carbohydrate. A type of molecule may be a polypeptide (e.g., a protein). A type of molecule may be a highly functionalized nucleic acid polymer. A type of molecule may be a chemical compound. A chemical compound may be less than or equal to about 1000 Daltons (Da), 900 Da, 800 Da, 700 Da, 600 Da, 500 Da, 400 Da, 300 Da, or less in size.
• A set of molecules may comprise one or more unique molecules of a single type. A set may be a set of individual molecules (e.g., individual DNA molecules, individual RNA molecules, individual polypeptide molecules, etc.). Each molecule in a set of individual molecules may comprise two or more segments. A molecule may comprise at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 segments, or more. A molecule may comprise at most 10, 9, 8, 7, 6, 5, 4, 3, or 2 segments. A segment may be a DNA segment. A DNA segment may comprise one or more nucleotides. A DNA segment may comprise a barcode sequence. A segment may be an RNA segment. An RNA segment may comprise one or more nucleotides. A segment may be a polypeptide segment. A polypeptide segment may comprise one or more amino acids. Segments may be combined using combinatorial methods as described herein, thereby generating a set of unique molecules. For example, a set of molecules, where each molecule comprises three segments selected from 96 different segments can comprise up to 884,736 unique molecules.
• A set may be a set of chemical compound combinations, where each combination comprises molecules of a single type. For example, a set of compound combinations may be a set of drug combinations comprising two or more different drug combinations. A compound combination may comprise any number of individual compounds. A compound combination may comprise at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50 or more individual compounds. A compound combination may comprise at most 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, or 2 individual compounds. For example, a drug combination in a set of drug combinations may comprise at least 2 individual drugs in a single, unique combination. A set of compound combinations may be generated using the combinatorial methods described herein, thereby generating a set of unique molecule combinations. For example, a set of compound combinations, where each compound combination comprises three different compounds (e.g., drugs) selected from 96 different compounds can comprise up to 884,736 unique molecule combinations.
Chemical Compounds
• A chemical compound can be covalently linked to a support (e.g., bead) by a variety of methods. For example, an amide bond can be formed between the chemical compound and a support. In this case, a support (e.g., a gel bead) may comprise a carboxylate group and/or an amine group, thereby facilitating formation of an amide bond between the chemical compound and support. Amide bond formation can require that a chemical compound comprises a free carboxylate or amine group. Additional methods can be used to link a chemical compound to a support. Non-limiting examples of chemical conjugation methods include disulfide conjugations, thioether conjugations, Diels-Alder reactions, inverse electron-deficient Diels-Alder reactions, and azide-alkyne cycloadditions. In some cases, self-immolative linkers can be used to attach chemical compounds to a support. Self-immolative linkers may be useful in, for example, releasing chemical compounds from a support. Upon activation, self-immolative linkers may become labile and the chemical compound can be released from the linker. Self-immolative linkers can be activated by various mechanisms including, for example, enzymatic, redox, nucleophilic, acid-base, and photonic stimuli. Activation of a self-immolative linker may be useful in releasing one or more chemical compounds (e.g., a set of chemical compound combinations) from a support.
• A chemical compound can be captured in a bead. To prevent undesired diffusion of chemical compounds, a barrier can be engineered on the surface of the bead. For example, a sol-gel film can be formed on the surface of a bead, thereby retaining chemical compounds (e.g., a set of chemical compound combinations) within a bead. In some cases, chemical compounds can be encapsulated in a vesicle in a bead. For example, a chemical compound in a partition may be encapsulated in a vesicle. A vesicle comprising a chemical compound may be attached to or captured in a bead, thereby capturing the chemical compound in the bead. The vesicle surface can maintain bead association through covalent or non-covalent interactions. The vesicle-encapsulated chemical compounds can be released from the vesicles using a variety of mechanisms including solubilization using surfactants, enzymatic degradation, chemical degradation, and temperature cycling. Non-limiting examples of vesicles include liposomes, micelles, and polymersomes.
Polypeptides
• Polypeptides can be produced using de novo designed peptide synthesis techniques in which peptides are formed by successive additions of individual amino acids. Non-limiting examples of peptide synthesis methods include solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and native chemical ligation. SPPS involves repeated cycles of coupling, washing, deprotection, and washing. In SPPS, the C-terminus of the first amino acid is coupled to an activated solid support that is chemically inert. The solid support acts as the C-terminal protecting group such that the immobilized protein is retained during a filtration process while liquid-phase reagents and reaction by-products are washed away. The free N-terminal amine of a solid support attached peptide is coupled to a single N-protected amino acid unit. This unit is then deprotected to reveal a new N-terminal amine to which a further amino acid can be attached. The peptide can be assembled by the successive additions of protected amino acids followed by deprotection. Supports of the present disclosure (e.g., beads, gel beads) can be used in polypeptide synthesis methods for generation of a polypeptide. Supports may comprise amine groups, thereby facilitating polypeptide synthesis. Individual operations of polypeptide synthesis methods may be performed within a partition, thereby attaching individual polypeptide segments (e.g., individual amino acids) to a bead in each partition of the combinatorial methods described herein. Non-limiting examples of protecting groups include tert-butylether, tert-butylester, tert-butyloxycarbonyl (t-Boc), and 9-fluorenyl methoxycarbonyl (Fmoc). Coupling agents include, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride (DMTMM).
• Bioconjugation reactions can be used to conjugate a polypeptide segment comprising natural or non-natural amino acids into a growing polypeptide. Such reactions include, for example, the alkyne/azide click chemistry, carbonyl condensations, Michael-type additions, and Mizoroki-Heck substitutions. Polypeptides can be produced using SpyTag/SpyCatcher reaction mechanisms. SpyTag/SpyCatcher is generated by splitting the CnaB2 domain from fibronectin-binding protein FbaB fromStreptococcus pyogenes(Spy) into a 13-residue peptide (SpyTag) and the 116-residue complementary domain (SpyCatcher). These two parts spontaneously reconstitute to form an isopeptide bond under a range of temperatures, pH values, buffers, and detergents. SpyTag/SpyCatcher reaction mechanisms can be used to attach a polypeptide segment to another polypeptide segment. For example, a polypeptide segment in a partition may be attached to a polypeptide segment attached to a support using a SpyTag/SpyCatcher reaction mechanism.
• Polypeptides can be produced by assembly of short peptides. Individual peptides can be conjugated on the surface of a bead by repeated cycles of coupling, washing, deprotection, and washing. In some cases, peptides can be synthesized using a combination of enzymatic addition and chemical deprotection reactions.
Systems and Methods for Sample Compartmentalization
• In an aspect, the systems and methods described herein provide for the compartmentalization, depositing, or partitioning of one or more particles (e.g., biological particles, macromolecular constituents of biological particles, beads, reagents, etc.) into discrete compartments or partitions (referred to interchangeably herein as partitions), where each partition maintains separation of its own contents from the contents of other partitions. The partition can be a droplet in an emulsion. A partition may comprise one or more other partitions.
• A partition may include one or more particles. A partition may include one or more types of particles. For example, a partition of the present disclosure may comprise one or more biological particles and/or macromolecular constituents thereof. A partition may comprise one or more gel beads. A partition may comprise one or more cell beads. A partition may include a single gel bead, a single cell bead, or both a single cell bead and single gel bead. A partition may include one or more reagents. Alternatively, a partition may be unoccupied. For example, a partition may not comprise a bead. A cell bead can be a biological particle and/or one or more of its macromolecular constituents encased inside of a gel or polymer matrix, such as via polymerization of a droplet containing the biological particle and precursors capable of being polymerized or gelled. Unique identifiers, such as barcodes, may be injected into the droplets previous to, subsequent to, or concurrently with droplet generation, such as via a microcapsule (e.g., bead), as described elsewhere herein. Microfluidic channel networks (e.g., on a chip) can be utilized to generate partitions as described herein. Alternative mechanisms may also be employed in the partitioning of individual biological particles, including porous membranes through which aqueous mixtures of cells are extruded into non-aqueous fluids.
• The partitions can be flowable within fluid streams. The partitions may comprise, for example, micro-vesicles that have an outer barrier surrounding an inner fluid center or core. In some cases, the partitions may comprise a porous matrix that is capable of entraining and/or retaining materials within its matrix. The partitions can be droplets of a first phase within a second phase, wherein the first and second phases are immiscible. For example, the partitions can be droplets of aqueous fluid within a non-aqueous continuous phase (e.g., oil phase). In another example, the partitions can be droplets of a non-aqueous fluid within an aqueous phase. In some examples, the partitions may be provided in a water-in-oil emulsion or oil-in-water emulsion. A variety of different vessels are described in, for example, U.S. Patent Application Publication No. 2014/0155295, which is entirely incorporated herein by reference for all purposes. Emulsion systems for creating stable droplets in non-aqueous or oil continuous phases are described in, for example, U.S. Patent Application Publication No. 2010/0105112, which is entirely incorporated herein by reference for all purposes.
• In the case of droplets in an emulsion, allocating individual particles to discrete partitions may in one non-limiting example be accomplished by introducing a flowing stream of particles in an aqueous fluid into a flowing stream of a non-aqueous fluid, such that droplets are generated at the junction of the two streams. Fluid properties (e.g., fluid flow rates, fluid viscosities, etc.), particle properties (e.g., volume fraction, particle size, particle concentration, etc.), microfluidic architectures (e.g., channel geometry, etc.), and other parameters may be adjusted to control the occupancy of the resulting partitions (e.g., number of biological particles per partition, number of beads per partition, etc.). For example, partition occupancy can be controlled by providing the aqueous stream at a certain concentration and/or flow rate of particles. To generate single biological particle partitions, the relative flow rates of the immiscible fluids can be selected such that, on average, the partitions may contain less than one biological particle per partition in order to ensure that those partitions that are occupied are primarily singly occupied. In some cases, partitions among a plurality of partitions may contain at most one biological particle (e.g., bead, DNA, cell or cellular material). In some embodiments, the various parameters (e.g., fluid properties, particle properties, microfluidic architectures, etc.) may be selected or adjusted such that a majority of partitions are occupied, for example, allowing for only a small percentage of unoccupied partitions. The flows and channel architectures can be controlled as to ensure a given number of singly occupied partitions, less than a certain level of unoccupied partitions and/or less than a certain level of multiply occupied partitions.
• FIG. 1 shows an example of amicrofluidic channel structure100 for partitioning individual biological particles. Thechannel structure100 can includechannel segments102,104,106 and108 communicating at achannel junction110. In operation, a firstaqueous fluid112 that includes suspended biological particles (or cells)114 may be transported alongchannel segment102 intojunction110, while asecond fluid116 that is immiscible with theaqueous fluid112 is delivered to thejunction110 from each ofchannel segments104 and106 to creatediscrete droplets118,120 of the firstaqueous fluid112 flowing intochannel segment108, and flowing away fromjunction110. Thechannel segment108 may be fluidically coupled to an outlet reservoir where the discrete droplets can be stored and/or harvested. A discrete droplet generated may include an individual biological particle114 (such as droplets118). A discrete droplet generated may include more than one individual biological particle114 (not shown inFIG. 1). A discrete droplet may contain no biological particle114 (such as droplet120). Each discrete partition may maintain separation of its own contents (e.g., individual biological particle114) from the contents of other partitions.
• Thesecond fluid116 can comprise an oil, such as a fluorinated oil, that includes a fluorosurfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resultingdroplets118,120. Examples of particularly useful partitioning fluids and fluorosurfactants are described, for example, in U.S. Patent Application Publication No. 2010/0105112, which is entirely incorporated herein by reference for all purposes.
• As will be appreciated, the channel segments described herein may be coupled to any of a variety of different fluid sources or receiving components, including reservoirs, tubing, manifolds, or fluidic components of other systems. As will be appreciated, themicrofluidic channel structure100 may have other geometries. For example, a microfluidic channel structure can have more than one channel junction. For example, a microfluidic channel structure can have 2, 3, 4, or 5 channel segments each carrying particles (e.g., biological particles, cell beads, and/or gel beads) that meet at a channel junction. Fluid may be directed to flow along one or more channels or reservoirs via one or more fluid flow units. A fluid flow unit can comprise compressors (e.g., providing positive pressure), pumps (e.g., providing negative pressure), actuators, and the like to control flow of the fluid. Fluid may also or otherwise be controlled via applied pressure differentials, centrifugal force, electrokinetic pumping, vacuum, capillary or gravity flow, or the like.
• The generated droplets may comprise two subsets of droplets: (1) occupieddroplets118, containing one or morebiological particles114, and (2)unoccupied droplets120, not containing anybiological particles114.Occupied droplets118 may comprise singly occupied droplets (having one biological particle) and multiply occupied droplets (having more than one biological particle). As described elsewhere herein, in some cases, the majority of occupied partitions can include no more than one biological particle per occupied partition and some of the generated partitions can be unoccupied (of any biological particle). In some cases, though, some of the occupied partitions may include more than one biological particle. In some cases, the partitioning process may be controlled such that fewer than about 25% of the occupied partitions contain more than one biological particle, and in many cases, fewer than about 20% of the occupied partitions have more than one biological particle, while in some cases, fewer than about 10% or even fewer than about 5% of the occupied partitions include more than one biological particle per partition.
• In some cases, it may be desirable to minimize the creation of excessive numbers of empty partitions, such as to reduce costs and/or increase efficiency. While this minimization may be achieved by providing a sufficient number of biological particles (e.g., biological particles114) at thepartitioning junction110, such as to ensure that at least one biological particle is encapsulated in a partition, the Poissonian distribution may expectedly increase the number of partitions that include multiple biological particles. As such, where singly occupied partitions are to be obtained, at most about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5% or less of the generated partitions can be unoccupied.
• In some cases, the flow of one or more of the biological particles (e.g., in channel segment102), or other fluids directed into the partitioning junction (e.g., inchannel segments104,106) can be controlled such that, in many cases, no more than about 50% of the generated partitions, no more than about 25% of the generated partitions, or no more than about 10% of the generated partitions are unoccupied. These flows can be controlled so as to present a non-Poissonian distribution of single-occupied partitions while providing lower levels of unoccupied partitions. The above noted ranges of unoccupied partitions can be achieved while still providing any of the single occupancy rates described above. For example, in many cases, the use of the systems and methods described herein can create resulting partitions that have multiple occupancy rates of less than about 25%, less than about 20%, less than about 15%, less than about 10%, and in many cases, less than about 5%, while having unoccupied partitions of less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%, less than about 5%, or less.
• As will be appreciated, the above-described occupancy rates are also applicable to partitions that include both biological particles and additional reagents, including, but not limited to, microcapsules or beads (e.g., gel beads) carrying barcoded nucleic acid molecules (e.g., oligonucleotides) (described in relation toFIG. 2). The occupied partitions (e.g., at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% of the occupied partitions) can include both a microcapsule (e.g., bead) comprising barcoded nucleic acid molecules and a biological particle.
• In another aspect, in addition to or as an alternative to droplet based partitioning, biological particles may be encapsulated within a microcapsule that comprises an outer shell, layer or porous matrix in which is entrained one or more individual biological particles or small groups of biological particles. The microcapsule may include other reagents. Encapsulation of biological particles may be performed by a variety of processes. Such processes may combine an aqueous fluid containing the biological particles with a polymeric precursor material that may be capable of being formed into a gel or other solid or semi-solid matrix upon application of a particular stimulus to the polymer precursor. Such stimuli can include, for example, thermal stimuli (e.g., either heating or cooling), photo-stimuli (e.g., through photo-curing), chemical stimuli (e.g., through crosslinking, polymerization initiation of the precursor (e.g., through added initiators)), mechanical stimuli, or a combination thereof.
• Preparation of microcapsules comprising biological particles may be performed by a variety of methods. For example, air knife droplet or aerosol generators may be used to dispense droplets of precursor fluids into gelling solutions in order to form microcapsules that include individual biological particles or small groups of biological particles. Likewise, membrane based encapsulation systems may be used to generate microcapsules comprising encapsulated biological particles as described herein. Microfluidic systems of the present disclosure, such as that shown inFIG. 1, may be readily used in encapsulating cells as described herein. In particular, and with reference toFIG. 1, theaqueous fluid112 comprising (i) thebiological particles114 and (ii) the polymer precursor material (not shown) is flowed intochannel junction110, where it is partitioned intodroplets118,120 through the flow ofnon-aqueous fluid116. In the case of encapsulation methods,non-aqueous fluid116 may also include an initiator (not shown) to cause polymerization and/or crosslinking of the polymer precursor to form the microcapsule that includes the entrained biological particles. Examples of polymer precursor/initiator pairs include those described in U.S. Patent Application Publication No. 2014/0378345, which is entirely incorporated herein by reference for all purposes.
• For example, in the case where the polymer precursor material comprises a linear polymer material, such as a linear polyacrylamide, PEG, or other linear polymeric material, the activation agent may comprise a cross-linking agent, or a chemical that activates a cross-linking agent within the formed droplets. Likewise, for polymer precursors that comprise polymerizable monomers, the activation agent may comprise a polymerization initiator. For example, in certain cases, where the polymer precursor comprises a mixture of acrylamide monomer with a N,N′-bis-(acryloyl)cystamine (BAC) comonomer, an agent such as tetraethylmethylenediamine (TEMED) may be provided within the second fluid streams116 inchannel segments104 and106, which can initiate the copolymerization of the acrylamide and BAC into a cross-linked polymer network, or hydrogel.
• Upon contact of thesecond fluid stream116 with the firstfluid stream112 atjunction110, during formation of droplets, the TEMED may diffuse from thesecond fluid116 into theaqueous fluid112 comprising the linear polyacrylamide, which will activate the crosslinking of the polyacrylamide within thedroplets118,120, resulting in the formation of gel (e.g., hydrogel) microcapsules, as solid or semi-solid beads or particles entraining thecells114. Although described in terms of polyacrylamide encapsulation, other ‘activatable’ encapsulation compositions may also be employed in the context of the methods and compositions described herein. For example, formation of alginate droplets followed by exposure to divalent metal ions (e.g., Ca′ ions), can be used as an encapsulation process using the described processes. Likewise, agarose droplets may also be transformed into capsules through temperature based gelling (e.g., upon cooling, etc.).
• In some cases, encapsulated biological particles can be selectively releasable from the microcapsule, such as through passage of time or upon application of a particular stimulus, that degrades the microcapsule sufficiently to allow the biological particles (e.g., cell), or its other contents to be released from the microcapsule, such as into a partition (e.g., droplet). For example, in the case of the polyacrylamide polymer described above, degradation of the microcapsule may be accomplished through the introduction of an appropriate reducing agent, such as DTT or the like, to cleave disulfide bonds that cross-link the polymer matrix. See, for example, U.S. Patent Application Publication No. 2014/0378345, which is entirely incorporated herein by reference for all purposes.
• The biological particle can be subjected to other conditions sufficient to polymerize or gel the precursors. The conditions sufficient to polymerize or gel the precursors may comprise exposure to heating, cooling, electromagnetic radiation, and/or light. The conditions sufficient to polymerize or gel the precursors may comprise any conditions sufficient to polymerize or gel the precursors. Following polymerization or gelling, a polymer or gel may be formed around the biological particle. The polymer or gel may be diffusively permeable to chemical or biochemical reagents. The polymer or gel may be diffusively impermeable to macromolecular constituents of the biological particle. In this manner, the polymer or gel may act to allow the biological particle to be subjected to chemical or biochemical operations while spatially confining the macromolecular constituents to a region of the droplet defined by the polymer or gel. The polymer or gel may include one or more of disulfide cross-linked polyacrylamide, agarose, alginate, polyvinyl alcohol, polyethylene glycol (PEG)-diacrylate, PEG-acrylate, PEG-thiol, PEG-azide, PEG-alkyne, other acrylates, chitosan, hyaluronic acid, collagen, fibrin, gelatin, or elastin. The polymer or gel may comprise any other polymer or gel.
• The polymer or gel may be functionalized to bind to targeted analytes, such as nucleic acids, proteins, carbohydrates, lipids or other analytes. The polymer or gel may be polymerized or gelled via a passive mechanism. The polymer or gel may be stable in alkaline conditions or at elevated temperature. The polymer or gel may have mechanical properties similar to the mechanical properties of the bead. For instance, the polymer or gel may be of a similar size to the bead. The polymer or gel may have a mechanical strength (e.g. tensile strength) similar to that of the bead. The polymer or gel may be of a lower density than an oil. The polymer or gel may be of a density that is roughly similar to that of a buffer. The polymer or gel may have a tunable pore size. The pore size may be chosen to, for instance, retain denatured nucleic acids. The pore size may be chosen to maintain diffusive permeability to exogenous chemicals such as sodium hydroxide (NaOH) and/or endogenous chemicals such as inhibitors. The polymer or gel may be biocompatible. The polymer or gel may maintain or enhance cell viability. The polymer or gel may be biochemically compatible. The polymer or gel may be polymerized and/or depolymerized thermally, chemically, enzymatically, and/or optically.
• The polymer may comprise poly(acrylamide-co-acrylic acid) crosslinked with disulfide linkages. The preparation of the polymer may comprise a two-step reaction. In the first activation step, poly(acrylamide-co-acrylic acid) may be exposed to an acylating agent to convert carboxylic acids to esters. For instance, the poly(acrylamide-co-acrylic acid) may be exposed to 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM). The polyacrylamide-co-acrylic acid may be exposed to other salts of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium. In the second cross-linking step, the ester formed in the first step may be exposed to a disulfide crosslinking agent. For instance, the ester may be exposed to cystamine (2,2′-dithiobis(ethylamine)). Following the two steps, the biological particle may be surrounded by polyacrylamide strands linked together by disulfide bridges. In this manner, the biological particle may be encased inside of or comprise a gel or matrix (e.g., polymer matrix) to form a “cell bead.” A cell bead can contain biological particles (e.g., a cell) or macromolecular constituents (e.g., RNA, DNA, proteins, etc.) of biological particles. A cell bead may include a single cell or multiple cells, or a derivative of the single cell or multiple cells. For example after lysing and washing the cells, inhibitory components from cell lysates can be washed away and the macromolecular constituents can be bound as cell beads. Systems and methods disclosed herein can be applicable to both cell beads (and/or droplets or other partitions) containing biological particles and cell beads (and/or droplets or other partitions) containing macromolecular constituents of biological particles.
• Encapsulated biological particles can provide certain potential advantages of being more storable and more portable than droplet-based partitioned biological particles. Furthermore, in some cases, it may be desirable to allow biological particles to incubate for a select period of time before analysis, such as in order to characterize changes in such biological particles over time, either in the presence or absence of different stimuli. In such cases, encapsulation may allow for longer incubation than partitioning in emulsion droplets, although in some cases, droplet partitioned biological particles may also be incubated for different periods of time, e.g., at least 10 seconds, at least 30 seconds, at least 1 minute, at least 5 minutes, at least 10 minutes, at least 30 minutes, at least 1 hour, at least 2 hours, at least 5 hours, or at least 10 hours or more. The encapsulation of biological particles may constitute the partitioning of the biological particles into which other reagents are co-partitioned. Alternatively or in addition, encapsulated biological particles may be readily deposited into other partitions (e.g., droplets) as described above.
Beads
• A partition may comprise one or more unique identifiers, such as barcodes. Barcodes may be previously, subsequently or concurrently delivered to the partitions that hold the compartmentalized or partitioned biological particle. For example, barcodes may be injected into droplets previous to, subsequent to, or concurrently with droplet generation. The delivery of the barcodes to a particular partition allows for the later attribution of the characteristics of the individual biological particle to the particular partition. Barcodes may be delivered, for example on a nucleic acid molecule (e.g., an oligonucleotide), to a partition via any suitable mechanism. Barcoded nucleic acid molecules can be delivered to a partition via a microcapsule. A microcapsule, in some instances, can comprise a bead. Beads are described in further detail below.
• In some cases, barcoded nucleic acid molecules can be initially associated with the microcapsule and then released from the microcapsule. Release of the barcoded nucleic acid molecules can be passive (e.g., by diffusion out of the microcapsule). In addition or alternatively, release from the microcapsule can be upon application of a stimulus which allows the barcoded nucleic acid nucleic acid molecules to dissociate or to be released from the microcapsule. Such stimulus may disrupt the microcapsule, an interaction that couples the barcoded nucleic acid molecules to or within the microcapsule, or both. Such stimulus can include, for example, a thermal stimulus, photo-stimulus, chemical stimulus (e.g., change in pH or use of a reducing agent(s)), a mechanical stimulus, a radiation stimulus; a biological stimulus (e.g., enzyme), or any combination thereof.
• FIG. 2 shows an example of amicrofluidic channel structure200 for delivering barcode carrying beads to droplets. Thechannel structure200 can includechannel segments201,202,204,206 and208 communicating at achannel junction210. In operation, thechannel segment201 may transport anaqueous fluid212 that includes a plurality of beads214 (e.g., with nucleic acid molecules, oligonucleotides, molecular tags) along thechannel segment201 intojunction210. The plurality ofbeads214 may be sourced from a suspension of beads. For example, thechannel segment201 may be connected to a reservoir comprising an aqueous suspension ofbeads214. Thechannel segment202 may transport theaqueous fluid212 that includes a plurality ofbiological particles216 along thechannel segment202 intojunction210. The plurality ofbiological particles216 may be sourced from a suspension of biological particles. For example, thechannel segment202 may be connected to a reservoir comprising an aqueous suspension ofbiological particles216. In some instances, theaqueous fluid212 in either thefirst channel segment201 or thesecond channel segment202, or in both segments, can include one or more reagents, as further described below. Asecond fluid218 that is immiscible with the aqueous fluid212 (e.g., oil) can be delivered to thejunction210 from each ofchannel segments204 and206. Upon meeting of theaqueous fluid212 from each ofchannel segments201 and202 and thesecond fluid218 from each ofchannel segments204 and206 at thechannel junction210, theaqueous fluid212 can be partitioned asdiscrete droplets220 in thesecond fluid218 and flow away from thejunction210 alongchannel segment208. Thechannel segment208 may deliver the discrete droplets to an outlet reservoir fluidly coupled to thechannel segment208, where they may be harvested.
• As an alternative, thechannel segments201 and202 may meet at another junction upstream of thejunction210. At such junction, beads and biological particles may form a mixture that is directed along another channel to thejunction210 to yielddroplets220. The mixture may provide the beads and biological particles in an alternating fashion, such that, for example, a droplet comprises a single bead and a single biological particle.
• Beads, biological particles and droplets may flow along channels at substantially regular flow profiles (e.g., at regular flow rates). Such regular flow profiles may permit a droplet to include a single bead and a single biological particle. Such regular flow profiles may permit the droplets to have an occupancy (e.g., droplets having beads and biological particles) greater than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%. Such regular flow profiles and devices that may be used to provide such regular flow profiles are provided in, for example, U.S. Patent Publication No. 2015/0292988, which is entirely incorporated herein by reference.
• Thesecond fluid218 can comprise an oil, such as a fluorinated oil, that includes a fluorosurfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resultingdroplets220.
• A discrete droplet that is generated may include an individualbiological particle216. A discrete droplet that is generated may include a barcode or otherreagent carrying bead214. A discrete droplet generated may include both an individual biological particle and a barcode carrying bead, such asdroplets220. In some instances, a discrete droplet may include more than one individual biological particle or no biological particle. In some instances, a discrete droplet may include more than one bead or no bead. A discrete droplet may be unoccupied (e.g., no beads, no biological particles).
• Beneficially, a discrete droplet partitioning a biological particle and a barcode carrying bead may effectively allow the attribution of the barcode to macromolecular constituents of the biological particle within the partition. The contents of a partition may remain discrete from the contents of other partitions.
• As will be appreciated, the channel segments described herein may be coupled to any of a variety of different fluid sources or receiving components, including reservoirs, tubing, manifolds, or fluidic components of other systems. As will be appreciated, themicrofluidic channel structure200 may have other geometries. For example, a microfluidic channel structure can have more than one channel junctions. For example, a microfluidic channel structure can have 2, 3, 4, or 5 channel segments each carrying beads that meet at a channel junction. Fluid may be directed flow along one or more channels or reservoirs via one or more fluid flow units. A fluid flow unit can comprise compressors (e.g., providing positive pressure), pumps (e.g., providing negative pressure), actuators, and the like to control flow of the fluid. Fluid may also or otherwise be controlled via applied pressure differentials, centrifugal force, electrokinetic pumping, vacuum, capillary or gravity flow, or the like.
• A bead may be porous, non-porous, solid, semi-solid, semi-fluidic, fluidic, and/or a combination thereof. In some instances, a bead may be dissolvable, disruptable, and/or degradable. In some cases, a bead may not be degradable. In some cases, the bead may be a gel bead. A gel bead may be a hydrogel bead. A gel bead may be formed from molecular precursors, such as a polymeric or monomeric species. A semi-solid bead may be a liposomal bead. Solid beads may comprise metals including iron oxide, gold, and silver. In some cases, the bead may be a silica bead. In some cases, the bead can be rigid. In other cases, the bead may be flexible and/or compressible.
• A bead may be of any suitable shape. Examples of bead shapes include, but are not limited to, spherical, non-spherical, oval, oblong, amorphous, circular, cylindrical, and variations thereof.
• Beads may be of uniform size or heterogeneous size. In some cases, the diameter of a bead may be at least about 10 nanometers (nm), 100 nm, 500 nm, 1 micrometer (μm), 5 μm, 10 μm, 20 μm, 30 μm, 40 μm, 50 μm, 60 μm, 70 μm, 80 μm, 90 μm, 100 μm, 250 μm, 500 μm, 1 mm, or greater. In some cases, a bead may have a diameter of less than about 10 nm, 100 nm, 500 nm, lμm, 5 μm, 10 μm, 20 μm, 30 μm, 40 μm, 50 μm, 60 μm, 70 μm, 80 μm, 90 μm, 100 μm, 250 μm, 500 μm, 1 mm, or less. In some cases, a bead may have a diameter in the range of about 40-75 μm, 30-75 μm, 20-75 μm, 40-85 μm, 40-95 μm, 20-100 μm, 10-100 μm, 1-100 μm, 20-250 μm, or 20-500 μm.
• In certain aspects, beads can be provided as a population or plurality of beads having a relatively monodisperse size distribution. Where it may be desirable to provide relatively consistent amounts of reagents within partitions, maintaining relatively consistent bead characteristics, such as size, can contribute to the overall consistency. In particular, the beads described herein may have size distributions that have a coefficient of variation in their cross-sectional dimensions of less than 50%, less than 40%, less than 30%, less than 20%, and in some cases less than 15%, less than 10%, less than 5%, or less.
• A bead may comprise natural and/or synthetic materials. For example, a bead can comprise a natural polymer, a synthetic polymer or both natural and synthetic polymers. Examples of natural polymers include proteins and sugars such as deoxyribonucleic acid, rubber, cellulose, starch (e.g., amylose, amylopectin), proteins, enzymes, polysaccharides, silks, polyhydroxyalkanoates, chitosan, dextran, collagen, carrageenan, ispaghula, acacia, agar, gelatin, shellac, sterculia gum, xanthan gum, Corn sugar gum, guar gum, gum karaya, agarose, alginic acid, alginate, or natural polymers thereof. Examples of synthetic polymers include acrylics, nylons, silicones, spandex, viscose rayon, polycarboxylic acids, polyvinyl acetate, polyacrylamide, polyacrylate, polyethylene glycol, polyurethanes, polylactic acid, silica, polystyrene, polyacrylonitrile, polybutadiene, polycarbonate, polyethylene, polyethylene terephthalate, poly(chlorotrifluoroethylene), poly(ethylene oxide), poly(ethylene terephthalate), polyethylene, polyisobutylene, poly(methyl methacrylate), poly(oxymethylene), polyformaldehyde, polypropylene, polystyrene, poly(tetrafluoroethylene), poly(vinyl acetate), poly(vinyl alcohol), poly(vinyl chloride), poly(vinylidene dichloride), poly(vinylidene difluoride), poly(vinyl fluoride) and/or combinations (e.g., co-polymers) thereof. Beads may also be formed from materials other than polymers, including lipids, micelles, ceramics, glass-ceramics, material composites, metals, other inorganic materials, and others.
• In some instances, the bead may contain molecular precursors (e.g., monomers or polymers), which may form a polymer network via polymerization of the molecular precursors. In some cases, a precursor may be an already polymerized species capable of undergoing further polymerization via, for example, a chemical cross-linkage. In some cases, a precursor can comprise one or more of an acrylamide or a methacrylamide monomer, oligomer, or polymer. In some cases, the bead may comprise prepolymers, which are oligomers capable of further polymerization. For example, polyurethane beads may be prepared using prepolymers. In some cases, the bead may contain individual polymers that may be further polymerized together. In some cases, beads may be generated via polymerization of different precursors, such that they comprise mixed polymers, co-polymers, and/or block co-polymers. In some cases, the bead may comprise covalent or ionic bonds between polymeric precursors (e.g., monomers, oligomers, linear polymers), nucleic acid molecules (e.g., oligonucleotides), primers, and other entities. In some cases, the covalent bonds can be carbon-carbon bonds, thioether bonds, or carbon-heteroatom bonds.
• Cross-linking may be permanent or reversible, depending upon the particular cross-linker used. Reversible cross-linking may allow for the polymer to linearize or dissociate under appropriate conditions. In some cases, reversible cross-linking may also allow for reversible attachment of a material bound to the surface of a bead. In some cases, a cross-linker may form disulfide linkages. In some cases, the chemical cross-linker forming disulfide linkages may be cystamine or a modified cystamine.
• In some cases, disulfide linkages can be formed between molecular precursor units (e.g., monomers, oligomers, or linear polymers) or precursors incorporated into a bead and nucleic acid molecules (e.g., oligonucleotides). Cystamine (including modified cystamines), for example, is an organic agent comprising a disulfide bond that may be used as a crosslinker agent between individual monomeric or polymeric precursors of a bead. Polyacrylamide may be polymerized in the presence of cystamine or a species comprising cystamine (e.g., a modified cystamine) to generate polyacrylamide gel beads comprising disulfide linkages (e.g., chemically degradable beads comprising chemically-reducible cross-linkers). The disulfide linkages may permit the bead to be degraded (or dissolved) upon exposure of the bead to a reducing agent.
• In some cases, chitosan, a linear polysaccharide polymer, may be crosslinked with glutaraldehyde via hydrophilic chains to form a bead. Crosslinking of chitosan polymers may be achieved by chemical reactions that are initiated by heat, pressure, change in pH, and/or radiation.
• In some cases, a bead may comprise a moiety, which in certain aspects may be used for attachment of a polypeptide (e.g., a protein) to the bead.FIG. 12 illustrates examples of moieties for use in attachment of a polypeptide to a bead. A bead may comprise a monomer capable of serving as a chelator (e.g., iminodiacetic acid, nitrilotriacetic acid or carboxylmethylaspartate). A monomer capable of serving as a chelator may serve to attach a polypeptide to a bead via a histidine tag. A bead may comprise a monomer comprising a streptavidin protein (e.g., an acroyl-streptavidin monomer). A streptavidin protein may be used to attach a molecule (e.g., a polypeptide) to a bead via a streptavidin-biotin linkage. A bead may comprise an aptamer molecule. A bead may comprise an antibody or antibody fragment.
• In some cases, a bead may comprise an acrydite moiety, which in certain aspects may be used to attach one or more nucleic acid molecules (e.g., barcode sequence, barcoded nucleic acid molecule, barcoded oligonucleotide, primer, or other oligonucleotide) to the bead. In some cases, an acrydite moiety can refer to an acrydite analogue generated from the reaction of acrydite with one or more species, such as, the reaction of acrydite with other monomers and cross-linkers during a polymerization reaction. Acrydite moieties may be modified to form chemical bonds with a species to be attached, such as a nucleic acid molecule (e.g., barcode sequence, barcoded nucleic acid molecule, barcoded oligonucleotide, primer, or other oligonucleotide). Acrydite moieties may be modified with thiol groups capable of forming a disulfide bond or may be modified with groups already comprising a disulfide bond. The thiol or disulfide (via disulfide exchange) may be used as an anchor point for a species to be attached or another part of the acrydite moiety may be used for attachment. In some cases, attachment can be reversible, such that when the disulfide bond is broken (e.g., in the presence of a reducing agent), the attached species is released from the bead. In other cases, an acrydite moiety can comprise a reactive hydroxyl group that may be used for attachment.
• Functionalization of beads for attachment of nucleic acid molecules (e.g., oligonucleotides) may be achieved through a wide range of different approaches, including activation of chemical groups within a polymer, incorporation of active or activatable functional groups in the polymer structure, or attachment at the pre-polymer or monomer stage in bead production.
• For example, precursors (e.g., monomers, cross-linkers) that are polymerized to form a bead may comprise acrydite moieties, such that when a bead is generated, the bead also comprises acrydite moieties. The acrydite moieties can be attached to a nucleic acid molecule (e.g., oligonucleotide), which may include a priming sequence (e.g., a primer for amplifying target nucleic acids, random primer, primer sequence for messenger RNA) and/or one or more barcode sequences. The one more barcode sequences may include sequences that are the same for all nucleic acid molecules coupled to a given bead and/or sequences that are different across all nucleic acid molecules coupled to the given bead. The nucleic acid molecule may be incorporated into the bead.
• In some cases, the nucleic acid molecule can comprise a functional sequence, for example, for attachment to a sequencing flow cell, such as, for example, a P5 sequence for Illumina® sequencing. In some cases, the nucleic acid molecule or derivative thereof (e.g., oligonucleotide or polynucleotide generated from the nucleic acid molecule) can comprise another functional sequence, such as, for example, a P7 sequence for attachment to a sequencing flow cell for Illumina sequencing. In some cases, the nucleic acid molecule can comprise a barcode sequence. In some cases, the primer can further comprise a unique molecular identifier (UMI). In some cases, the primer can comprise an R1 primer sequence for Illumina sequencing. In some cases, the primer can comprise an R2 primer sequence for Illumina sequencing. Examples of such nucleic acid molecules (e.g., oligonucleotides, polynucleotides, etc.) and uses thereof, as may be used with compositions, devices, methods and systems of the present disclosure, are provided in U.S. Patent Pub. Nos. 2014/0378345 and 2015/0376609, each of which is entirely incorporated herein by reference.
• FIG. 8 illustrates an example of a barcode carrying bead. Anucleic acid molecule802, such as an oligonucleotide, can be coupled to abead804 by areleasable linkage806, such as, for example, a disulfide linker. Thesame bead804 may be coupled (e.g., via releasable linkage) to one or more othernucleic acid molecules818,820. Thenucleic acid molecule802 may be or comprise a barcode. As noted elsewhere herein, the structure of the barcode may comprise a number of sequence elements. Thenucleic acid molecule802 may comprise afunctional sequence808 that may be used in subsequent processing. For example, thefunctional sequence808 may include one or more of a sequencer specific flow cell attachment sequence (e.g., a P5 sequence for Illumina® sequencing systems) and a sequencing primer sequence (e.g., a R1 primer for Illumina® sequencing systems). Thenucleic acid molecule802 may comprise abarcode sequence810 for use in barcoding the sample (e.g., DNA, RNA, protein, etc.). In some cases, thebarcode sequence810 can be bead-specific such that thebarcode sequence810 is common to all nucleic acid molecules (e.g., including nucleic acid molecule802) coupled to thesame bead804. Alternatively or in addition, thebarcode sequence810 can be partition-specific such that thebarcode sequence810 is common to all nucleic acid molecules coupled to one or more beads that are partitioned into the same partition. Thenucleic acid molecule802 may comprise aspecific priming sequence812, such as an mRNA specific priming sequence (e.g., poly-T sequence), a targeted priming sequence, and/or a random priming sequence. Thenucleic acid molecule802 may comprise ananchoring sequence814 to ensure that thespecific priming sequence812 hybridizes at the sequence end (e.g., of the mRNA). For example, theanchoring sequence814 can include a random short sequence of nucleotides, such as a 1-mer, 2-mer, 3-mer or longer sequence, which can ensure that a poly-T segment is more likely to hybridize at the sequence end of the poly-A tail of the mRNA.
• Thenucleic acid molecule802 may comprise a unique molecular identifying sequence816 (e.g., unique molecular identifier (UMI)). In some cases, the unique molecular identifyingsequence816 may comprise from about 5 to about 8 nucleotides. Alternatively, the unique molecular identifyingsequence816 may compress less than about 5 or more than about 8 nucleotides. The unique molecular identifyingsequence816 may be a unique sequence that varies across individual nucleic acid molecules (e.g.,802,818,820, etc.) coupled to a single bead (e.g., bead804). In some cases, the unique molecular identifyingsequence816 may be a random sequence (e.g., such as a random N-mer sequence). For example, the UMI may provide a unique identifier of the starting mRNA molecule that was captured, in order to allow quantitation of the number of original expressed RNA. As will be appreciated, althoughFIG. 8 shows threenucleic acid molecules802,818,820 coupled to the surface of thebead804, an individual bead may be coupled to any number of individual nucleic acid molecules, for example, from one to tens to hundreds of thousands or even millions of individual nucleic acid molecules. The respective barcodes for the individual nucleic acid molecules can comprise both common sequence segments or relatively common sequence segments (e.g.,808,810,812, etc.) and variable or unique sequence segments (e.g.,816) between different individual nucleic acid molecules coupled to the same bead.
• In operation, a biological particle (e.g., cell, DNA, RNA, etc.) can be co-partitioned along with abarcode bearing bead804. The barcodednucleic acid molecules802,818,820 can be released from thebead804 in the partition. By way of example, in the context of analyzing sample RNA, the poly-T segment (e.g.,812) of one of the released nucleic acid molecules (e.g.,802) can hybridize to the poly-A tail of a mRNA molecule. Reverse transcription may result in a cDNA transcript of the mRNA, but which transcript includes each of thesequence segments808,810,816 of thenucleic acid molecule802. Because thenucleic acid molecule802 comprises ananchoring sequence814, it will more likely hybridize to and prime reverse transcription at the sequence end of the poly-A tail of the mRNA. Within any given partition, all of the cDNA transcripts of the individual mRNA molecules may include a commonbarcode sequence segment810. However, the transcripts made from the different mRNA molecules within a given partition may vary at the unique molecular identifyingsequence812 segment (e.g., UMI segment). Beneficially, even following any subsequent amplification of the contents of a given partition, the number of different UMIs can be indicative of the quantity of mRNA originating from a given partition, and thus from the biological particle (e.g., cell). As noted above, the transcripts can be amplified, cleaned up and sequenced to identify the sequence of the cDNA transcript of the mRNA, as well as to sequence the barcode segment and the UMI segment. While a poly-T primer sequence is described, other targeted or random priming sequences may also be used in priming the reverse transcription reaction. Likewise, although described as releasing the barcoded oligonucleotides into the partition, in some cases, the nucleic acid molecules bound to the bead (e.g., gel bead) may be used to hybridize and capture the mRNA on the solid phase of the bead, for example, in order to facilitate the separation of the RNA from other cell contents.
• In some cases, precursors comprising a functional group that is reactive or capable of being activated such that it becomes reactive can be polymerized with other precursors to generate gel beads comprising the activated or activatable functional group. The functional group may then be used to attach additional species (e.g., disulfide linkers, primers, other oligonucleotides, etc.) to the gel beads. For example, some precursors comprising a carboxylic acid (COOH) group can co-polymerize with other precursors to form a gel bead that also comprises a COOH functional group. In some cases, acrylic acid (a species comprising free COOH groups), acrylamide, and bis(acryloyl)cystamine can be co-polymerized together to generate a gel bead comprising free COOH groups. The COOH groups of the gel bead can be activated (e.g., via 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-Hydroxysuccinimide (NETS) or 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM)) such that they are reactive (e.g., reactive to amine functional groups where EDC/NHS or DMTMM are used for activation). The activated COOH groups can then react with an appropriate species (e.g., a species comprising an amine functional group where the carboxylic acid groups are activated to be reactive with an amine functional group) comprising a moiety to be linked to the bead.
• Beads comprising disulfide linkages in their polymeric network may be functionalized with additional species via reduction of some of the disulfide linkages to free thiols. The disulfide linkages may be reduced via, for example, the action of a reducing agent (e.g., DTT, TCEP, etc.) to generate free thiol groups, without dissolution of the bead. Free thiols of the beads can then react with free thiols of a species or a species comprising another disulfide bond (e.g., via thiol-disulfide exchange) such that the species can be linked to the beads (e.g., via a generated disulfide bond). In some cases, free thiols of the beads may react with any other suitable group. For example, free thiols of the beads may react with species comprising an acrydite moiety. The free thiol groups of the beads can react with the acrydite via Michael addition chemistry, such that the species comprising the acrydite is linked to the bead. In some cases, uncontrolled reactions can be prevented by inclusion of a thiol capping agent such as N-ethylmalieamide or iodoacetate.
• Activation of disulfide linkages within a bead can be controlled such that only a small number of disulfide linkages are activated. Control may be exerted, for example, by controlling the concentration of a reducing agent used to generate free thiol groups and/or concentration of reagents used to form disulfide bonds in bead polymerization. In some cases, a low concentration (e.g., molecules of reducing agent:gel bead ratios of less than or equal to about 1:100,000,000,000, less than or equal to about 1:10,000,000,000, less than or equal to about 1:1,000,000,000, less than or equal to about 1:100,000,000, less than or equal to about 1:10,000,000, less than or equal to about 1:1,000,000, less than or equal to about 1:100,000, less than or equal to about 1:10,000) of reducing agent may be used for reduction. Controlling the number of disulfide linkages that are reduced to free thiols may be useful in ensuring bead structural integrity during functionalization. In some cases, optically-active agents, such as fluorescent dyes may be coupled to beads via free thiol groups of the beads and used to quantify the number of free thiols present in a bead and/or track a bead.
• In some cases, addition of moieties to a gel bead after gel bead formation may be advantageous. For example, addition of an oligonucleotide (e.g., barcoded oligonucleotide) after gel bead formation may avoid loss of the species during chain transfer termination that can occur during polymerization. Moreover, smaller precursors (e.g., monomers or cross linkers that do not comprise side chain groups and linked moieties) may be used for polymerization and can be minimally hindered from growing chain ends due to viscous effects. In some cases, functionalization after gel bead synthesis can minimize exposure of species (e.g., oligonucleotides) to be loaded with potentially damaging agents (e.g., free radicals) and/or chemical environments. In some cases, the generated gel may possess an upper critical solution temperature (UCST) that can permit temperature driven swelling and collapse of a bead. Such functionality may aid in oligonucleotide (e.g., a primer) infiltration into the bead during subsequent functionalization of the bead with the oligonucleotide. Post-production functionalization may also be useful in controlling loading ratios of species in beads, such that, for example, the variability in loading ratio is minimized. Species loading may also be performed in a batch process such that a plurality of beads can be functionalized with the species in a single batch.
• A bead injected or otherwise introduced into a partition may comprise releasably, cleavably, or reversibly attached barcodes. A bead injected or otherwise introduced into a partition may comprise activatable barcodes. A bead injected or otherwise introduced into a partition may be degradable, disruptable, or dissolvable beads.
• Barcodes can be releasably, cleavably or reversibly attached to the beads such that barcodes can be released or be releasable through cleavage of a linkage between the barcode molecule and the bead, or released through degradation of the underlying bead itself, allowing the barcodes to be accessed or be accessible by other reagents, or both. In non-limiting examples, cleavage may be achieved through reduction of di-sulfide bonds, use of restriction enzymes, photo-activated cleavage, or cleavage via other types of stimuli (e.g., chemical, thermal, pH, enzymatic, etc.) and/or reactions, such as described elsewhere herein. Releasable barcodes may sometimes be referred to as being activatable, in that they are available for reaction once released. Thus, for example, an activatable barcode may be activated by releasing the barcode from a bead (or other suitable type of partition described herein). Other activatable configurations are also envisioned in the context of the described methods and systems.
• In addition to, or as an alternative to the cleavable linkages between the beads and the associated molecules, such as barcode containing nucleic acid molecules (e.g., barcoded oligonucleotides), the beads may be degradable, disruptable, or dissolvable spontaneously or upon exposure to one or more stimuli (e.g., temperature changes, pH changes, exposure to particular chemical species or phase, exposure to light, reducing agent, etc.). In some cases, a bead may be dissolvable, such that material components of the beads are solubilized when exposed to a particular chemical species or an environmental change, such as a change temperature or a change in pH. In some cases, a gel bead can be degraded or dissolved at elevated temperature and/or in basic conditions. In some cases, a bead may be thermally degradable such that when the bead is exposed to an appropriate change in temperature (e.g., heat), the bead degrades. Degradation or dissolution of a bead bound to a species (e.g., a nucleic acid molecule, e.g., barcoded oligonucleotide) may result in release of the species from the bead.
• As will be appreciated from the above disclosure, the degradation of a bead may refer to the disassociation of a bound or entrained species from a bead, both with and without structurally degrading the physical bead itself. For example, the degradation of the bead may involve cleavage of a cleavable linkage via one or more species and/or methods described elsewhere herein. In another example, entrained species may be released from beads through osmotic pressure differences due to, for example, changing chemical environments. By way of example, alteration of bead pore sizes due to osmotic pressure differences can generally occur without structural degradation of the bead itself. In some cases, an increase in pore size due to osmotic swelling of a bead can permit the release of entrained species within the bead. In other cases, osmotic shrinking of a bead may cause a bead to better retain an entrained species due to pore size contraction.
• A degradable bead may be introduced into a partition, such as a droplet of an emulsion or a well, such that the bead degrades within the partition and any associated species (e.g., oligonucleotides) are released within the droplet when the appropriate stimulus is applied. The free species (e.g., oligonucleotides, nucleic acid molecules) may interact with other reagents contained in the partition. For example, a polyacrylamide bead comprising cystamine and linked, via a disulfide bond, to a barcode sequence, may be combined with a reducing agent within a droplet of a water-in-oil emulsion. Within the droplet, the reducing agent can break the various disulfide bonds, resulting in bead degradation and release of the barcode sequence into the aqueous, inner environment of the droplet. In another example, heating of a droplet comprising a bead-bound barcode sequence in basic solution may also result in bead degradation and release of the attached barcode sequence into the aqueous, inner environment of the droplet.
• Any suitable number of molecular tag molecules (e.g., primer, barcoded oligonucleotide) can be associated with a bead such that, upon release from the bead, the molecular tag molecules (e.g., primer, e.g., barcoded oligonucleotide) are present in the partition at a pre-defined concentration. Such pre-defined concentration may be selected to facilitate certain reactions for generating a sequencing library, e.g., amplification, within the partition. In some cases, the pre-defined concentration of the primer can be limited by the process of producing nucleic acid molecule (e.g., oligonucleotide) bearing beads.
• In some cases, beads can be non-covalently loaded with one or more reagents. The beads can be non-covalently loaded by, for instance, subjecting the beads to conditions sufficient to swell the beads, allowing sufficient time for the reagents to diffuse into the interiors of the beads, and subjecting the beads to conditions sufficient to de-swell the beads. The swelling of the beads may be accomplished, for instance, by placing the beads in a thermodynamically favorable solvent, subjecting the beads to a higher or lower temperature, subjecting the beads to a higher or lower ion concentration, and/or subjecting the beads to an electric field. The swelling of the beads may be accomplished by various swelling methods. The de-swelling of the beads may be accomplished, for instance, by transferring the beads in a thermodynamically unfavorable solvent, subjecting the beads to lower or high temperatures, subjecting the beads to a lower or higher ion concentration, and/or removing an electric field. The de-swelling of the beads may be accomplished by various de-swelling methods. Transferring the beads may cause pores in the bead to shrink. The shrinking may then hinder reagents within the beads from diffusing out of the interiors of the beads. The hindrance may be due to steric interactions between the reagents and the interiors of the beads. The transfer may be accomplished microfluidically. For instance, the transfer may be achieved by moving the beads from one co-flowing solvent stream to a different co-flowing solvent stream. The swellability and/or pore size of the beads may be adjusted by changing the polymer composition of the bead.
• In some cases, an acrydite moiety linked to a precursor, another species linked to a precursor, or a precursor itself can comprise a labile bond, such as chemically, thermally, or photo-sensitive bond e.g., disulfide bond, UV sensitive bond, or the like. Once acrydite moieties or other moieties comprising a labile bond are incorporated into a bead, the bead may also comprise the labile bond. The labile bond may be, for example, useful in reversibly linking (e.g., covalently linking) species (e.g., barcodes, primers, etc.) to a bead. In some cases, a thermally labile bond may include a nucleic acid hybridization based attachment, e.g., where an oligonucleotide is hybridized to a complementary sequence that is attached to the bead, such that thermal melting of the hybrid releases the oligonucleotide, e.g., a barcode containing sequence, from the bead or microcapsule.
• The addition of multiple types of labile bonds to a gel bead may result in the generation of a bead capable of responding to varied stimuli. Each type of labile bond may be sensitive to an associated stimulus (e.g., chemical stimulus, light, temperature, enzymatic, etc.) such that release of species attached to a bead via each labile bond may be controlled by the application of the appropriate stimulus. Such functionality may be useful in controlled release of species from a gel bead. In some cases, another species comprising a labile bond may be linked to a gel bead after gel bead formation via, for example, an activated functional group of the gel bead as described above. As will be appreciated, barcodes that are releasably, cleavably or reversibly attached to the beads described herein include barcodes that are released or releasable through cleavage of a linkage between the barcode molecule and the bead, or that are released through degradation of the underlying bead itself, allowing the barcodes to be accessed or accessible by other reagents, or both.
• The barcodes that are releasable as described herein may sometimes be referred to as being activatable, in that they are available for reaction once released. Thus, for example, an activatable barcode may be activated by releasing the barcode from a bead (or other suitable type of partition described herein). Other activatable configurations are also envisioned in the context of the described methods and systems.
• In addition to thermally cleavable bonds, disulfide bonds and UV sensitive bonds, other non-limiting examples of labile bonds that may be coupled to a precursor or bead include an ester linkage (e.g., cleavable with an acid, a base, or hydroxylamine), a vicinal diol linkage (e.g., cleavable via sodium periodate), a Diels-Alder linkage (e.g., cleavable via heat), a sulfone linkage (e.g., cleavable via a base), a silyl ether linkage (e.g., cleavable via an acid), a glycosidic linkage (e.g., cleavable via an amylase), a peptide linkage (e.g., cleavable via a protease), or a phosphodiester linkage (e.g., cleavable via a nuclease (e.g., DNAase)). A bond may be cleavable via other nucleic acid molecule targeting enzymes, such as restriction enzymes (e.g., restriction endonucleases), as described further below.
• Species may be encapsulated in beads during bead generation (e.g., during polymerization of precursors). Such species may or may not participate in polymerization. Such species may be entered into polymerization reaction mixtures such that generated beads comprise the species upon bead formation. In some cases, such species may be added to the gel beads after formation. Such species may include, for example, nucleic acid molecules (e.g., oligonucleotides), reagents for a nucleic acid amplification reaction (e.g., primers, polymerases, dNTPs, co-factors (e.g., ionic co-factors), buffers) including those described herein, reagents for enzymatic reactions (e.g., enzymes, co-factors, substrates, buffers), reagents for nucleic acid modification reactions such as polymerization, ligation, or digestion, and/or reagents for template preparation (e.g., tagmentation) for one or more sequencing platforms (e.g., Nextera® for Illumina®). Such species may include one or more enzymes described herein, including without limitation, polymerase, reverse transcriptase, restriction enzymes (e.g., endonuclease), transposase, ligase, proteinase K, DNAse, etc. Such species may include one or more reagents described elsewhere herein (e.g., lysis agents, inhibitors, inactivating agents, chelating agents, stimulus). Trapping of such species may be controlled by the polymer network density generated during polymerization of precursors, control of ionic charge within the gel bead (e.g., via ionic species linked to polymerized species), or by the release of other species. Encapsulated species may be released from a bead upon bead degradation and/or by application of a stimulus capable of releasing the species from the bead. Alternatively or in addition, species may be partitioned in a partition (e.g., droplet) during or subsequent to partition formation. Such species may include, without limitation, the abovementioned species that may also be encapsulated in a bead.
• A degradable bead may comprise one or more species with a labile bond such that, when the bead/species is exposed to the appropriate stimuli, the bond is broken and the bead degrades. The labile bond may be a chemical bond (e.g., covalent bond, ionic bond) or may be another type of physical interaction (e.g., van der Waals interactions, dipole-dipole interactions, etc.). In some cases, a crosslinker used to generate a bead may comprise a labile bond. Upon exposure to the appropriate conditions, the labile bond can be broken and the bead degraded. For example, upon exposure of a polyacrylamide gel bead comprising cystamine crosslinkers to a reducing agent, the disulfide bonds of the cystamine can be broken and the bead degraded.
• A degradable bead may be useful in more quickly releasing an attached species (e.g., a nucleic acid molecule, a barcode sequence, a primer, etc) from the bead when the appropriate stimulus is applied to the bead as compared to a bead that does not degrade. For example, for a species bound to an inner surface of a porous bead or in the case of an encapsulated species, the species may have greater mobility and accessibility to other species in solution upon degradation of the bead. In some cases, a species may also be attached to a degradable bead via a degradable linker (e.g., disulfide linker). The degradable linker may respond to the same stimuli as the degradable bead or the two degradable species may respond to different stimuli. For example, a barcode sequence may be attached, via a disulfide bond, to a polyacrylamide bead comprising cystamine. Upon exposure of the barcoded-bead to a reducing agent, the bead degrades and the barcode sequence is released upon breakage of both the disulfide linkage between the barcode sequence and the bead and the disulfide linkages of the cystamine in the bead.
• As will be appreciated from the above disclosure, while referred to as degradation of a bead, in many instances as noted above, that degradation may refer to the disassociation of a bound or entrained species from a bead, both with and without structurally degrading the physical bead itself. For example, entrained species may be released from beads through osmotic pressure differences due to, for example, changing chemical environments. By way of example, alteration of bead pore sizes due to osmotic pressure differences can generally occur without structural degradation of the bead itself. In some cases, an increase in pore size due to osmotic swelling of a bead can permit the release of entrained species within the bead. In other cases, osmotic shrinking of a bead may cause a bead to better retain an entrained species due to pore size contraction.
• Where degradable beads are provided, it may be beneficial to avoid exposing such beads to the stimulus or stimuli that cause such degradation prior to a given time, in order to, for example, avoid premature bead degradation and issues that arise from such degradation, including for example poor flow characteristics and aggregation. By way of example, where beads comprise reducible cross-linking groups, such as disulfide groups, it will be desirable to avoid contacting such beads with reducing agents, e.g., DTT or other disulfide cleaving reagents. In such cases, treatment to the beads described herein will, in some cases be provided free of reducing agents, such as DTT. Because reducing agents are often provided in commercial enzyme preparations, it may be desirable to provide reducing agent free (or DTT free) enzyme preparations in treating the beads described herein. Examples of such enzymes include, e.g., polymerase enzyme preparations, reverse transcriptase enzyme preparations, ligase enzyme preparations, as well as many other enzyme preparations that may be used to treat the beads described herein. The terms “reducing agent free” or “DTT free” preparations can refer to a preparation having less than about 1/10th, less than about 1/50th, or even less than about 1/100th of the lower ranges for such materials used in degrading the beads. For example, for DTT, the reducing agent free preparation can have less than about 0.01 millimolar (mM), 0.005 mM, 0.001 mM DTT, 0.0005 mM DTT, or even less than about 0.0001 mM DTT. In many cases, the amount of DTT can be undetectable.
• Numerous chemical triggers may be used to trigger the degradation of beads. Examples of these chemical changes may include, but are not limited to pH-mediated changes to the integrity of a component within the bead, degradation of a component of a bead via cleavage of cross-linked bonds, and depolymerization of a component of a bead.
• In some embodiments, a bead may be formed from materials that comprise degradable chemical crosslinkers, such as BAC or cystamine. Degradation of such degradable crosslinkers may be accomplished through a number of mechanisms. In some examples, a bead may be contacted with a chemical degrading agent that may induce oxidation, reduction or other chemical changes. For example, a chemical degrading agent may be a reducing agent, such as dithiothreitol (DTT). Additional examples of reducing agents may include β-mercaptoethanol, (2S)-2-amino-1,4-dimercaptobutane (dithiobutylamine or DTBA), tris(2-carboxyethyl) phosphine (TCEP), or combinations thereof. A reducing agent may degrade the disulfide bonds formed between gel precursors forming the bead, and thus, degrade the bead. In other cases, a change in pH of a solution, such as an increase in pH, may trigger degradation of a bead. In other cases, exposure to an aqueous solution, such as water, may trigger hydrolytic degradation, and thus degradation of the bead. In some cases, any combination of stimuli may trigger degradation of a bead. For example, a change in pH may enable a chemical agent (e.g., DTT) to become an effective reducing agent.
• Beads may also be induced to release their contents upon the application of a thermal stimulus. A change in temperature can cause a variety of changes to a bead. For example, heat can cause a solid bead to liquefy. A change in heat may cause melting of a bead such that a portion of the bead degrades. In other cases, heat may increase the internal pressure of the bead components such that the bead ruptures or explodes. Heat may also act upon heat-sensitive polymers used as materials to construct beads.
• Any suitable agent may degrade beads. In some embodiments, changes in temperature or pH may be used to degrade thermo-sensitive or pH-sensitive bonds within beads. In some embodiments, chemical degrading agents may be used to degrade chemical bonds within beads by oxidation, reduction or other chemical changes. For example, a chemical degrading agent may be a reducing agent, such as DTT, wherein DTT may degrade the disulfide bonds formed between a crosslinker and gel precursors, thus degrading the bead. In some embodiments, a reducing agent may be added to degrade the bead, which may or may not cause the bead to release its contents. Examples of reducing agents may include dithiothreitol (DTT), β-mercaptoethanol, (2S)-2-amino-1,4-dimercaptobutane (dithiobutylamine or DTBA), tris(2-carboxyethyl) phosphine (TCEP), or combinations thereof. The reducing agent may be present at a concentration of about 0.1 mM, 0.5 mM, 1 mM, 5 mM, 10 mM. The reducing agent may be present at a concentration of at least about 0.1 mM, 0.5 mM, 1 mM, 5 mM, 10 mM, or greater than 10 mM. The reducing agent may be present at concentration of at most about 10 mM, 5 mM, 1 mM, 0.5 mM, 0.1 mM, or less.
• Any suitable number of molecular tag molecules (e.g., primer, barcoded oligonucleotide) can be associated with a bead such that, upon release from the bead, the molecular tag molecules (e.g., primer, e.g., barcoded oligonucleotide) are present in the partition at a pre-defined concentration. Such pre-defined concentration may be selected to facilitate certain reactions for generating a sequencing library, e.g., amplification, within the partition. In some cases, the pre-defined concentration of the primer can be limited by the process of producing oligonucleotide bearing beads.
• AlthoughFIG. 1 andFIG. 2 have been described in terms of providing substantially singly occupied partitions, above, in certain cases, it may be desirable to provide multiply occupied partitions, e.g., containing two, three, four or more cells and/or microcapsules (e.g., beads) comprising barcoded nucleic acid molecules (e.g., oligonucleotides) within a single partition. Accordingly, as noted above, the flow characteristics of the biological particle and/or bead containing fluids and partitioning fluids may be controlled to provide for such multiply occupied partitions. In particular, the flow parameters may be controlled to provide a given occupancy rate at greater than about 50% of the partitions, greater than about 75%, and in some cases greater than about 80%, 90%, 95%, or higher.
• In some cases, additional microcapsules can be used to deliver additional reagents to a partition. In such cases, it may be advantageous to introduce different beads into a common channel or droplet generation junction, from different bead sources (e.g., containing different associated reagents) through different channel inlets into such common channel or droplet generation junction (e.g., junction210). In such cases, the flow and frequency of the different beads into the channel or junction may be controlled to provide for a certain ratio of microcapsules from each source, while ensuring a given pairing or combination of such beads into a partition with a given number of biological particles (e.g., one biological particle and one bead per partition).
• The partitions described herein may comprise small volumes, for example, less than about 10 microliters (μL), 5 μL, 1 μL, 900 picoliters (pL), 800 pL, 700 pL, 600 pL, 500 pL, 400 pL, 300 pL, 200 pL, 100 pL, 50 pL, 20 pL, 10 pL, 1 pL, 500 nanoliters (nL), 100 nL, 50 nL, or less.
• For example, in the case of droplet based partitions, the droplets may have overall volumes that are less than about 1000 pL, 900 pL, 800 pL, 700 pL, 600 pL, 500 pL, 400 pL, 300 pL, 200 pL, 100 pL, 50 pL, 20 pL, 10 pL, 1 pL, or less. Where co-partitioned with microcapsules, it will be appreciated that the sample fluid volume, e.g., including co-partitioned biological particles and/or beads, within the partitions may be less than about 90% of the above described volumes, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, or less than about 10% of the above described volumes.
• As is described elsewhere herein, partitioning species may generate a population or plurality of partitions. In such cases, any suitable number of partitions can be generated or otherwise provided. For example, at least about 1,000 partitions, at least about 5,000 partitions, at least about 10,000 partitions, at least about 50,000 partitions, at least about 100,000 partitions, at least about 500,000 partitions, at least about 1,000,000 partitions, at least about 5,000,000 partitions at least about 10,000,000 partitions, at least about 50,000,000 partitions, at least about 100,000,000 partitions, at least about 500,000,000 partitions, at least about 1,000,000,000 partitions, or more partitions can be generated or otherwise provided. Moreover, the plurality of partitions may comprise both unoccupied partitions (e.g., empty partitions) and occupied partitions.
Reagents
• In accordance with certain aspects, biological particles may be partitioned along with lysis reagents in order to release the contents of the biological particles within the partition. In such cases, the lysis agents can be contacted with the biological particle suspension concurrently with, or immediately prior to, the introduction of the biological particles into the partitioning junction/droplet generation zone (e.g., junction210), such as through an additional channel or channels upstream of the channel junction. In accordance with other aspects, additionally or alternatively, biological particles may be partitioned along with other reagents, as will be described further below.
• FIG. 3 shows an example of amicrofluidic channel structure300 for co-partitioning biological particles and reagents. Thechannel structure300 can includechannel segments301,302,304,306 and308.Channel segments301 and302 communicate at afirst channel junction309.Channel segments302,304,306, and308 communicate at asecond channel junction310.
• In an example operation, thechannel segment301 may transport anaqueous fluid312 that includes a plurality ofbiological particles314 along thechannel segment301 into thesecond junction310. As an alternative or in addition to,channel segment301 may transport beads (e.g., gel beads). The beads may comprise barcode molecules.
• For example, thechannel segment301 may be connected to a reservoir comprising an aqueous suspension ofbiological particles314. Upstream of, and immediately prior to reaching, thesecond junction310, thechannel segment301 may meet thechannel segment302 at thefirst junction309. Thechannel segment302 may transport a plurality of reagents315 (e.g., lysis agents) suspended in theaqueous fluid312 along thechannel segment302 into thefirst junction309. For example, thechannel segment302 may be connected to a reservoir comprising thereagents315. After thefirst junction309, theaqueous fluid312 in thechannel segment301 can carry both thebiological particles314 and thereagents315 towards thesecond junction310. In some instances, theaqueous fluid312 in thechannel segment301 can include one or more reagents, which can be the same or different reagents as thereagents315. Asecond fluid316 that is immiscible with the aqueous fluid312 (e.g., oil) can be delivered to thesecond junction310 from each ofchannel segments304 and306. Upon meeting of theaqueous fluid312 from thechannel segment301 and thesecond fluid316 from each ofchannel segments304 and306 at thesecond channel junction310, theaqueous fluid312 can be partitioned asdiscrete droplets318 in thesecond fluid316 and flow away from thesecond junction310 alongchannel segment308. Thechannel segment308 may deliver thediscrete droplets318 to an outlet reservoir fluidly coupled to thechannel segment308, where they may be harvested.
• Thesecond fluid316 can comprise an oil, such as a fluorinated oil, that includes a fluorosurfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resultingdroplets318.
• A discrete droplet generated may include an individualbiological particle314 and/or one ormore reagents315. In some instances, a discrete droplet generated may include a barcode carrying bead (not shown), such as via other microfluidics structures described elsewhere herein. In some instances, a discrete droplet may be unoccupied (e.g., no reagents, no biological particles).
• Beneficially, when lysis reagents and biological particles are co-partitioned, the lysis reagents can facilitate the release of the contents of the biological particles within the partition. The contents released in a partition may remain discrete from the contents of other partitions.
• As will be appreciated, the channel segments described herein may be coupled to any of a variety of different fluid sources or receiving components, including reservoirs, tubing, manifolds, or fluidic components of other systems. As will be appreciated, themicrofluidic channel structure300 may have other geometries. For example, a microfluidic channel structure can have more than two channel junctions. For example, a microfluidic channel structure can have 2, 3, 4, 5 channel segments or more each carrying the same or different types of beads, reagents, and/or biological particles that meet at a channel junction. Fluid flow in each channel segment may be controlled to control the partitioning of the different elements into droplets. Fluid may be directed flow along one or more channels or reservoirs via one or more fluid flow units. A fluid flow unit can comprise compressors (e.g., providing positive pressure), pumps (e.g., providing negative pressure), actuators, and the like to control flow of the fluid. Fluid may also or otherwise be controlled via applied pressure differentials, centrifugal force, electrokinetic pumping, vacuum, capillary or gravity flow, or the like.
• Examples of lysis agents include bioactive reagents, such as lysis enzymes that are used for lysis of different cell types, e.g., gram positive or negative bacteria, plants, yeast, mammalian, etc., such as lysozymes, achromopeptidase, lysostaphin, labiase, kitalase, lyticase, and a variety of other lysis enzymes available from, e.g., Sigma-Aldrich, Inc. (St Louis, Mo.), as well as other commercially available lysis enzymes. Other lysis agents may additionally or alternatively be co-partitioned with the biological particles to cause the release of the biological particles's contents into the partitions. For example, in some cases, surfactant-based lysis solutions may be used to lyse cells, although these may be less desirable for emulsion based systems where the surfactants can interfere with stable emulsions. In some cases, lysis solutions may include non-ionic surfactants such as, for example, TritonX-100 and Tween 20. In some cases, lysis solutions may include ionic surfactants such as, for example, sarcosyl and sodium dodecyl sulfate (SDS). Electroporation, thermal, acoustic or mechanical cellular disruption may also be used in certain cases, e.g., non-emulsion based partitioning such as encapsulation of biological particles that may be in addition to or in place of droplet partitioning, where any pore size of the encapsulate is sufficiently small to retain nucleic acid fragments of a given size, following cellular disruption.
• Alternatively or in addition to the lysis agents co-partitioned with the biological particles described above, other reagents can also be co-partitioned with the biological particles, including, for example, DNase and RNase inactivating agents or inhibitors, such as proteinase K, chelating agents, such as EDTA, and other reagents employed in removing or otherwise reducing negative activity or impact of different cell lysate components on subsequent processing of nucleic acids. In addition, in the case of encapsulated biological particles, the biological particles may be exposed to an appropriate stimulus to release the biological particles or their contents from a co-partitioned microcapsule. For example, in some cases, a chemical stimulus may be co-partitioned along with an encapsulated biological particle to allow for the degradation of the microcapsule and release of the cell or its contents into the larger partition. In some cases, this stimulus may be the same as the stimulus described elsewhere herein for release of nucleic acid molecules (e.g., oligonucleotides) from their respective microcapsule (e.g., bead). In alternative aspects, this may be a different and non-overlapping stimulus, in order to allow an encapsulated biological particle to be released into a partition at a different time from the release of nucleic acid molecules into the same partition.
• Additional reagents may also be co-partitioned with the biological particles, such as endonucleases to fragment a biological particle's DNA, DNA polymerase enzymes and dNTPs used to amplify the biological particle's nucleic acid fragments and to attach the barcode molecular tags to the amplified fragments. Other enzymes may be co-partitioned, including without limitation, polymerase, transposase, ligase, proteinase K, DNAse, etc. Additional reagents may also include reverse transcriptase enzymes, including enzymes with terminal transferase activity, primers and oligonucleotides, and switch oligonucleotides (also referred to herein as “switch oligos” or “template switching oligonucleotides”) which can be used for template switching. In some cases, template switching can be used to increase the length of a cDNA. In some cases, template switching can be used to append a predefined nucleic acid sequence to the cDNA. In an example of template switching, cDNA can be generated from reverse transcription of a template, e.g., cellular mRNA, where a reverse transcriptase with terminal transferase activity can add additional nucleotides, e.g., polyC, to the cDNA in a template independent manner. Switch oligos can include sequences complementary to the additional nucleotides, e.g., polyG. The additional nucleotides (e.g., polyC) on the cDNA can hybridize to the additional nucleotides (e.g., polyG) on the switch oligo, whereby the switch oligo can be used by the reverse transcriptase as template to further extend the cDNA. Template switching oligonucleotides may comprise a hybridization region and a template region. The hybridization region can comprise any sequence capable of hybridizing to the target. In some cases, as previously described, the hybridization region comprises a series of G bases to complement the overhanging C bases at the 3′ end of a cDNA molecule. The series of G bases may comprise 1 G base, 2 G bases, 3 G bases, 4 G bases, 5 G bases or more than 5 G bases. The template sequence can comprise any sequence to be incorporated into the cDNA. In some cases, the template region comprises at least 1 (e.g., at least 2, 3, 4, 5 or more) tag sequences and/or functional sequences. Switch oligos may comprise deoxyribonucleic acids; ribonucleic acids; modified nucleic acids including 2-Aminopurine, 2,6-Diaminopurine (2-Amino-dA), inverted dT, 5-Methyl dC, 2′-deoxyInosine, Super T (5-hydroxybutynl-2′-deoxyuridine), Super G (8-aza-7-deazaguanosine), locked nucleic acids (LNAs), unlocked nucleic acids (UNAs, e.g., UNA-A, UNA-U, UNA-C, UNA-G), Iso-dG, Iso-dC, 2′ Fluoro bases (e.g., Fluoro C, Fluoro U, Fluoro A, and Fluoro G), or any combination.
• In some cases, the length of a switch oligo may be at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249 or 250 nucleotides or longer.
• In some cases, the length of a switch oligo may be at most about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249 or 250 nucleotides.
• Once the contents of the cells are released into their respective partitions, the macromolecular components (e.g., macromolecular constituents of biological particles, such as RNA, DNA, or proteins) contained therein may be further processed within the partitions. In accordance with the methods and systems described herein, the macromolecular component contents of individual biological particles can be provided with unique identifiers such that, upon characterization of those macromolecular components they may be attributed as having been derived from the same biological particle or particles. The ability to attribute characteristics to individual biological particles or groups of biological particles is provided by the assignment of unique identifiers specifically to an individual biological particle or groups of biological particles. Unique identifiers, e.g., in the form of nucleic acid barcodes can be assigned or associated with individual biological particles or populations of biological particles, in order to tag or label the biological particle's macromolecular components (and as a result, its characteristics) with the unique identifiers. These unique identifiers can then be used to attribute the biological particle's components and characteristics to an individual biological particle or group of biological particles.
• In some aspects, this is performed by co-partitioning the individual biological particle or groups of biological particles with the unique identifiers, such as described above (with reference toFIG. 2). In some aspects, the unique identifiers are provided in the form of nucleic acid molecules (e.g., oligonucleotides) that comprise nucleic acid barcode sequences that may be attached to or otherwise associated with the nucleic acid contents of individual biological particle, or to other components of the biological particle, and particularly to fragments of those nucleic acids. The nucleic acid molecules are partitioned such that as between nucleic acid molecules in a given partition, the nucleic acid barcode sequences contained therein are the same, but as between different partitions, the nucleic acid molecule can, and do have differing barcode sequences, or at least represent a large number of different barcode sequences across all of the partitions in a given analysis. In some aspects, only one nucleic acid barcode sequence can be associated with a given partition, although in some cases, two or more different barcode sequences may be present.
• The nucleic acid barcode sequences can include from about 6 to about 20 or more nucleotides within the sequence of the nucleic acid molecules (e.g., oligonucleotides). The nucleic acid barcode sequences can include from about 6 to about 20, 30, 40, 50, 60, 70, 80, 90, 100 or more nucleotides. In some cases, the length of a barcode sequence may be about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides or longer. In some cases, the length of a barcode sequence may be at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides or longer. In some cases, the length of a barcode sequence may be at most about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides or shorter. These nucleotides may be completely contiguous, i.e., in a single stretch of adjacent nucleotides, or they may be separated into two or more separate subsequences that are separated by 1 or more nucleotides. In some cases, separated barcode subsequences can be from about 4 to about 16 nucleotides in length. In some cases, the barcode subsequence may be about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides or longer. In some cases, the barcode subsequence may be at least about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides or longer. In some cases, the barcode subsequence may be at most about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides or shorter.
• The co-partitioned nucleic acid molecules can also comprise other functional sequences useful in the processing of the nucleic acids from the co-partitioned biological particles. These sequences include, e.g., targeted or random/universal amplification primer sequences for amplifying the genomic DNA from the individual biological particles within the partitions while attaching the associated barcode sequences, sequencing primers or primer recognition sites, hybridization or probing sequences, e.g., for identification of presence of the sequences or for pulling down barcoded nucleic acids, or any of a number of other potential functional sequences. Other mechanisms of co-partitioning oligonucleotides may also be employed, including, e.g., coalescence of two or more droplets, where one droplet contains oligonucleotides, or microdispensing of oligonucleotides into partitions, e.g., droplets within microfluidic systems.
• In an example, microcapsules, such as beads, are provided that each include large numbers of the above described barcoded nucleic acid molecules (e.g., barcoded oligonucleotides) releasably attached to the beads, where all of the nucleic acid molecules attached to a particular bead will include the same nucleic acid barcode sequence, but where a large number of diverse barcode sequences are represented across the population of beads used. In some embodiments, hydrogel beads, e.g., comprising polyacrylamide polymer matrices, are used as a solid support and delivery vehicle for the nucleic acid molecules into the partitions, as they are capable of carrying large numbers of nucleic acid molecules, and may be configured to release those nucleic acid molecules upon exposure to a particular stimulus, as described elsewhere herein. In some cases, the population of beads provides a diverse barcode sequence library that includes at least about 1,000 different barcode sequences, at least about 5,000 different barcode sequences, at least about 10,000 different barcode sequences, at least about 50,000 different barcode sequences, at least about 100,000 different barcode sequences, at least about 1,000,000 different barcode sequences, at least about 5,000,000 different barcode sequences, or at least about 10,000,000 different barcode sequences, or more. Additionally, each bead can be provided with large numbers of nucleic acid (e.g., oligonucleotide) molecules attached. In particular, the number of molecules of nucleic acid molecules including the barcode sequence on an individual bead can be at least about 1,000 nucleic acid molecules, at least about 5,000 nucleic acid molecules, at least about 10,000 nucleic acid molecules, at least about 50,000 nucleic acid molecules, at least about 100,000 nucleic acid molecules, at least about 500,000 nucleic acids, at least about 1,000,000 nucleic acid molecules, at least about 5,000,000 nucleic acid molecules, at least about 10,000,000 nucleic acid molecules, at least about 50,000,000 nucleic acid molecules, at least about 100,000,000 nucleic acid molecules, at least about 250,000,000 nucleic acid molecules and in some cases at least about 1 billion nucleic acid molecules, or more. Nucleic acid molecules of a given bead can include identical (or common) barcode sequences, different barcode sequences, or a combination of both. Nucleic acid molecules of a given bead can include multiple sets of nucleic acid molecules. Nucleic acid molecules of a given set can include identical barcode sequences. The identical barcode sequences can be different from barcode sequences of nucleic acid molecules of another set.
• Moreover, when the population of beads is partitioned, the resulting population of partitions can also include a diverse barcode library that includes at least about 1,000 different barcode sequences, at least about 5,000 different barcode sequences, at least about 10,000 different barcode sequences, at least at least about 50,000 different barcode sequences, at least about 100,000 different barcode sequences, at least about 1,000,000 different barcode sequences, at least about 5,000,000 different barcode sequences, or at least about 10,000,000 different barcode sequences. Additionally, each partition of the population can include at least about 1,000 nucleic acid molecules, at least about 5,000 nucleic acid molecules, at least about 10,000 nucleic acid molecules, at least about 50,000 nucleic acid molecules, at least about 100,000 nucleic acid molecules, at least about 500,000 nucleic acids, at least about 1,000,000 nucleic acid molecules, at least about 5,000,000 nucleic acid molecules, at least about 10,000,000 nucleic acid molecules, at least about 50,000,000 nucleic acid molecules, at least about 100,000,000 nucleic acid molecules, at least about 250,000,000 nucleic acid molecules and in some cases at least about 1 billion nucleic acid molecules.
• In some cases, it may be desirable to incorporate multiple different barcodes within a given partition, either attached to a single or multiple beads within the partition. For example, in some cases, a mixed, but known set of barcode sequences may provide greater assurance of identification in the subsequent processing, e.g., by providing a stronger address or attribution of the barcodes to a given partition, as a duplicate or independent confirmation of the output from a given partition.
• The nucleic acid molecules (e.g., oligonucleotides) are releasable from the beads upon the application of a particular stimulus to the beads. In some cases, the stimulus may be a photo-stimulus, e.g., through cleavage of a photo-labile linkage that releases the nucleic acid molecules. In other cases, a thermal stimulus may be used, where elevation of the temperature of the beads environment will result in cleavage of a linkage or other release of the nucleic acid molecules form the beads. In still other cases, a chemical stimulus can be used that cleaves a linkage of the nucleic acid molecules to the beads, or otherwise results in release of the nucleic acid molecules from the beads. In one case, such compositions include the polyacrylamide matrices described above for encapsulation of biological particles, and may be degraded for release of the attached nucleic acid molecules through exposure to a reducing agent, such as DTT.
• In some aspects, provided are systems and methods for controlled partitioning. Droplet size may be controlled by adjusting certain geometric features in channel architecture (e.g., microfluidics channel architecture). For example, an expansion angle, width, and/or length of a channel may be adjusted to control droplet size.
• FIG. 4 shows an example of a microfluidic channel structure for the controlled partitioning of beads into discrete droplets. Achannel structure400 can include achannel segment402 communicating at a channel junction406 (or intersection) with areservoir404. Thereservoir404 can be a chamber. Any reference to “reservoir,” as used herein, can also refer to a “chamber.” In operation, anaqueous fluid408 that includes suspendedbeads412 may be transported along thechannel segment402 into thejunction406 to meet asecond fluid410 that is immiscible with theaqueous fluid408 in thereservoir404 to createdroplets416,418 of theaqueous fluid408 flowing into thereservoir404. At thejunction406 where theaqueous fluid408 and thesecond fluid410 meet, droplets can form based on factors such as the hydrodynamic forces at thejunction406, flow rates of the twofluids408,410, fluid properties, and certain geometric parameters (e.g., w, h₀, α, etc.) of thechannel structure400. A plurality of droplets can be collected in thereservoir404 by continuously injecting theaqueous fluid408 from thechannel segment402 through thejunction406.
• A discrete droplet generated may include a bead (e.g., as in occupied droplets416). Alternatively, a discrete droplet generated may include more than one bead. Alternatively, a discrete droplet generated may not include any beads (e.g., as in unoccupied droplet418). In some instances, a discrete droplet generated may contain one or more biological particles, as described elsewhere herein. In some instances, a discrete droplet generated may comprise one or more reagents, as described elsewhere herein.
• In some instances, theaqueous fluid408 can have a substantially uniform concentration or frequency ofbeads412. Thebeads412 can be introduced into thechannel segment402 from a separate channel (not shown inFIG. 4). The frequency ofbeads412 in thechannel segment402 may be controlled by controlling the frequency in which thebeads412 are introduced into thechannel segment402 and/or the relative flow rates of the fluids in thechannel segment402 and the separate channel. In some instances, the beads can be introduced into thechannel segment402 from a plurality of different channels, and the frequency controlled accordingly.
• In some instances, theaqueous fluid408 in thechannel segment402 can comprise biological particles (e.g., described with reference toFIGS. 1 and 2). In some instances, theaqueous fluid408 can have a substantially uniform concentration or frequency of biological particles. As with the beads, the biological particles can be introduced into thechannel segment402 from a separate channel. The frequency or concentration of the biological particles in theaqueous fluid408 in thechannel segment402 may be controlled by controlling the frequency in which the biological particles are introduced into thechannel segment402 and/or the relative flow rates of the fluids in thechannel segment402 and the separate channel. In some instances, the biological particles can be introduced into thechannel segment402 from a plurality of different channels, and the frequency controlled accordingly. In some instances, a first separate channel can introduce beads and a second separate channel can introduce biological particles into thechannel segment402. The first separate channel introducing the beads may be upstream or downstream of the second separate channel introducing the biological particles.
• Thesecond fluid410 can comprise an oil, such as a fluorinated oil, that includes a fluorosurfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resulting droplets.
• In some instances, thesecond fluid410 may not be subjected to and/or directed to any flow in or out of thereservoir404. For example, thesecond fluid410 may be substantially stationary in thereservoir404. In some instances, thesecond fluid410 may be subjected to flow within thereservoir404, but not in or out of thereservoir404, such as via application of pressure to thereservoir404 and/or as affected by the incoming flow of theaqueous fluid408 at thejunction406. Alternatively, thesecond fluid410 may be subjected and/or directed to flow in or out of thereservoir404. For example, thereservoir404 can be a channel directing thesecond fluid410 from upstream to downstream, transporting the generated droplets.
• Thechannel structure400 at or near thejunction406 may have certain geometric features that at least partly determine the sizes of the droplets formed by thechannel structure400. Thechannel segment402 can have a height, h₀and width, w, at or near thejunction406. By way of example, thechannel segment402 can comprise a rectangular cross-section that leads to areservoir404 having a wider cross-section (such as in width or diameter). Alternatively, the cross-section of thechannel segment402 can be other shapes, such as a circular shape, trapezoidal shape, polygonal shape, or any other shapes. The top and bottom walls of thereservoir404 at or near thejunction406 can be inclined at an expansion angle, α. The expansion angle, α, allows the tongue (portion of theaqueous fluid408 leavingchannel segment402 atjunction406 and entering thereservoir404 before droplet formation) to increase in depth and facilitate decrease in curvature of the intermediately formed droplet. Droplet size may decrease with increasing expansion angle. The resulting droplet radius, R_d, may be predicted by the following equation for the aforementioned geometric parameters of h₀, w, and α:
• $R_d\approx 0.44\left(1+2.2\sqrt{\tan \alpha }\frac{w}{h_0}\right)\frac{{\mathrm{<figure-callout\; label="h"\; filenames="US20190345636A1-20191114-D00006.png,US20190345636A1-20191114-D00010.png"\; state="\{\{state\}\}">h</figure-callout>}}_0}{\sqrt{\tan \alpha }}$
• By way of example, for a channel structure with w=21 μm, h=21 μm, and α=3°, the predicted droplet size is 121 μm. In another example, for a channel structure with w=25 h=25 μm, and α=5°, the predicted droplet size is 123 μm. In another example, for a channel structure with w=28 μm, h=28 μm, and α=7°, the predicted droplet size is 124 μm.
• In some instances, the expansion angle, α, may be between a range of from about 0.5° to about 4°, from about 0.1° to about 10°, or from about 0° to about 90°. For example, the expansion angle can be at least about 0.01°, 0.1°, 0.2°, 0.3°, 0.4°, 0.5°, 0.6°, 0.7°, 0.8°, 0.9°, 1°, 2°, 3°, 4°, 5°, 6°, 7°, 8°, 9°, 10°, 15°, 20°, 25°, 30°, 35°, 40°, 45°, 50°, 55°, 60°, 65°, 70°, 75°, 80°, 85°, or higher. In some instances, the expansion angle can be at most about 89°, 88°, 87°, 86°, 85°, 84°, 83°, 82°, 81°, 80°, 75°, 70°, 65°, 60°, 55°, 50°, 45°, 40°, 35°, 30°, 25°, 20°, 15°, 10°, 9°, 8°, 7°, 6°, 5°, 4°, 3°, 2°, 1°, 0.1°, 0.01°, or less. In some instances, the width, w, can be between a range of from about 100 micrometers (μm) to about 500 μm. In some instances, the width, w, can be between a range of from about 10 μm to about 200 μm. Alternatively, the width can be less than about 10 μm. Alternatively, the width can be greater than about 500 μm. In some instances, the flow rate of theaqueous fluid408 entering thejunction406 can be between about 0.04 microliters (μL)/minute (min) and about 40 μL/min. In some instances, the flow rate of theaqueous fluid408 entering thejunction406 can be between about 0.01 microliters (μL)/minute (min) and about 100 μL/min. Alternatively, the flow rate of theaqueous fluid408 entering thejunction406 can be less than about 0.01 μL/min. Alternatively, the flow rate of theaqueous fluid408 entering thejunction406 can be greater than about 40 μL/min, such as 45 μL/min, 50 μL/min, 55 μL/min, 60 μL/min, 65 μL/min, 70 μL/min, 75 μL/min, 80 μL/min, 85 μL/min, 90 μL/min, 95 μL/min, 100 μL/min, 110 μL/min, 120 μL/min, 130 μL/min, 140 μL/min, 150 μL/min, or greater. At lower flow rates, such as flow rates of about less than or equal to 10 microliters/minute, the droplet radius may not be dependent on the flow rate of theaqueous fluid408 entering thejunction406.
• In some instances, at least about 50% of the droplets generated can have uniform size. In some instances, at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater of the droplets generated can have uniform size. Alternatively, less than about 50% of the droplets generated can have uniform size.
• The throughput of droplet generation can be increased by increasing the points of generation, such as increasing the number of junctions (e.g., junction406) between aqueous fluid408 channel segments (e.g., channel segment402) and thereservoir404. Alternatively or in addition, the throughput of droplet generation can be increased by increasing the flow rate of theaqueous fluid408 in thechannel segment402.
• FIG. 5 shows an example of a microfluidic channel structure for increased droplet generation throughput. Amicrofluidic channel structure500 can comprise a plurality ofchannel segments502 and areservoir504. Each of the plurality ofchannel segments502 may be in fluid communication with thereservoir504. Thechannel structure500 can comprise a plurality ofchannel junctions506 between the plurality ofchannel segments502 and thereservoir504. Each channel junction can be a point of droplet generation. Thechannel segment402 from thechannel structure400 inFIG. 4 and any description to the components thereof may correspond to a given channel segment of the plurality ofchannel segments502 inchannel structure500 and any description to the corresponding components thereof. Thereservoir404 from thechannel structure400 and any description to the components thereof may correspond to thereservoir504 from thechannel structure500 and any description to the corresponding components thereof.
• Each channel segment of the plurality ofchannel segments502 may comprise anaqueous fluid508 that includes suspendedbeads512. Thereservoir504 may comprise asecond fluid510 that is immiscible with theaqueous fluid508. In some instances, thesecond fluid510 may not be subjected to and/or directed to any flow in or out of thereservoir504. For example, thesecond fluid510 may be substantially stationary in thereservoir504. In some instances, thesecond fluid510 may be subjected to flow within thereservoir504, but not in or out of thereservoir504, such as via application of pressure to thereservoir504 and/or as affected by the incoming flow of theaqueous fluid508 at the junctions. Alternatively, thesecond fluid510 may be subjected and/or directed to flow in or out of thereservoir504. For example, thereservoir504 can be a channel directing thesecond fluid510 from upstream to downstream, transporting the generated droplets.
• In operation, theaqueous fluid508 that includes suspendedbeads512 may be transported along the plurality ofchannel segments502 into the plurality ofjunctions506 to meet thesecond fluid510 in thereservoir504 to createdroplets516,518. A droplet may form from each channel segment at each corresponding junction with thereservoir504. At the junction where theaqueous fluid508 and thesecond fluid510 meet, droplets can form based on factors such as the hydrodynamic forces at the junction, flow rates of the twofluids508,510, fluid properties, and certain geometric parameters (e.g., w, h₀, α, etc.) of thechannel structure500, as described elsewhere herein. A plurality of droplets can be collected in thereservoir504 by continuously injecting theaqueous fluid508 from the plurality ofchannel segments502 through the plurality ofjunctions506. Throughput may significantly increase with the parallel channel configuration ofchannel structure500. For example, a channel structure having five inlet channel segments comprising theaqueous fluid508 may generate droplets five times as frequently than a channel structure having one inlet channel segment, provided that the fluid flow rate in the channel segments are substantially the same. The fluid flow rate in the different inlet channel segments may or may not be substantially the same. A channel structure may have as many parallel channel segments as is practical and allowed for the size of the reservoir. For example, the channel structure may have at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 500, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, 5000 or more parallel or substantially parallel channel segments.
• The geometric parameters, w, h₀, and α, may or may not be uniform for each of the channel segments in the plurality ofchannel segments502. For example, each channel segment may have the same or different widths at or near its respective channel junction with thereservoir504. For example, each channel segment may have the same or different height at or near its respective channel junction with thereservoir504. In another example, thereservoir504 may have the same or different expansion angle at the different channel junctions with the plurality ofchannel segments502. When the geometric parameters are uniform, beneficially, droplet size may also be controlled to be uniform even with the increased throughput. In some instances, when it is desirable to have a different distribution of droplet sizes, the geometric parameters for the plurality ofchannel segments502 may be varied accordingly.
• In some instances, at least about 50% of the droplets generated can have uniform size. In some instances, at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater of the droplets generated can have uniform size. Alternatively, less than about 50% of the droplets generated can have uniform size.
• FIG. 6 shows another example of a microfluidic channel structure for increased droplet generation throughput. Amicrofluidic channel structure600 can comprise a plurality ofchannel segments602 arranged generally circularly around the perimeter of areservoir604. Each of the plurality ofchannel segments602 may be in fluid communication with thereservoir604. Thechannel structure600 can comprise a plurality ofchannel junctions606 between the plurality ofchannel segments602 and thereservoir604. Each channel junction can be a point of droplet generation. Thechannel segment202 from thechannel structure200 inFIG. 2 and any description to the components thereof may correspond to a given channel segment of the plurality ofchannel segments602 inchannel structure600 and any description to the corresponding components thereof. Thereservoir204 from thechannel structure200 and any description to the components thereof may correspond to thereservoir604 from thechannel structure600 and any description to the corresponding components thereof.
• Each channel segment of the plurality ofchannel segments602 may comprise anaqueous fluid608 that includes suspendedbeads612. Thereservoir604 may comprise asecond fluid610 that is immiscible with theaqueous fluid608. In some instances, thesecond fluid610 may not be subjected to and/or directed to any flow in or out of thereservoir604. For example, thesecond fluid610 may be substantially stationary in thereservoir604. In some instances, thesecond fluid610 may be subjected to flow within thereservoir604, but not in or out of thereservoir604, such as via application of pressure to thereservoir604 and/or as affected by the incoming flow of theaqueous fluid608 at the junctions. Alternatively, thesecond fluid610 may be subjected and/or directed to flow in or out of thereservoir604. For example, thereservoir604 can be a channel directing thesecond fluid610 from upstream to downstream, transporting the generated droplets.
• In operation, theaqueous fluid608 that includes suspendedbeads612 may be transported along the plurality ofchannel segments602 into the plurality ofjunctions606 to meet thesecond fluid610 in thereservoir604 to create a plurality ofdroplets616. A droplet may form from each channel segment at each corresponding junction with thereservoir604. At the junction where theaqueous fluid608 and thesecond fluid610 meet, droplets can form based on factors such as the hydrodynamic forces at the junction, flow rates of the twofluids608,610, fluid properties, and certain geometric parameters (e.g., widths and heights of thechannel segments602, expansion angle of thereservoir604, etc.) of thechannel structure600, as described elsewhere herein. A plurality of droplets can be collected in thereservoir604 by continuously injecting theaqueous fluid608 from the plurality ofchannel segments602 through the plurality ofjunctions606. Throughput may significantly increase with the substantially parallel channel configuration of thechannel structure600. A channel structure may have as many substantially parallel channel segments as is practical and allowed for by the size of the reservoir. For example, the channel structure may have at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, 5000 or more parallel or substantially parallel channel segments. The plurality of channel segments may be substantially evenly spaced apart, for example, around an edge or perimeter of the reservoir. Alternatively, the spacing of the plurality of channel segments may be uneven.
• Thereservoir604 may have an expansion angle, α (not shown inFIG. 6) at or near each channel junction. Each channel segment of the plurality ofchannel segments602 may have a width, w, and a height, h₀, at or near the channel junction. The geometric parameters, w, h₀, and α, may or may not be uniform for each of the channel segments in the plurality ofchannel segments602. For example, each channel segment may have the same or different widths at or near its respective channel junction with thereservoir604. For example, each channel segment may have the same or different height at or near its respective channel junction with thereservoir604.
• Thereservoir604 may have the same or different expansion angle at the different channel junctions with the plurality ofchannel segments602. For example, a circular reservoir (as shown inFIG. 6) may have a conical, dome-like, or hemispherical ceiling (e.g., top wall) to provide the same or substantially same expansion angle for eachchannel segments602 at or near the plurality ofchannel junctions606. When the geometric parameters are uniform, beneficially, resulting droplet size may be controlled to be uniform even with the increased throughput. In some instances, when it is desirable to have a different distribution of droplet sizes, the geometric parameters for the plurality ofchannel segments602 may be varied accordingly.
• In some instances, at least about 50% of the droplets generated can have uniform size. In some instances, at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater of the droplets generated can have uniform size. Alternatively, less than about 50% of the droplets generated can have uniform size. The beads and/or biological particle injected into the droplets may or may not have uniform size.
• FIG. 7A shows a cross-section view of another example of a microfluidic channel structure with a geometric feature for controlled partitioning. Achannel structure700 can include achannel segment702 communicating at a channel junction706 (or intersection) with areservoir704. In some instances, thechannel structure700 and one or more of its components can correspond to thechannel structure100 and one or more of its components.FIG. 7B shows a perspective view of thechannel structure700 ofFIG. 7A.
• Anaqueous fluid712 comprising a plurality ofparticles716 may be transported along thechannel segment702 into thejunction706 to meet a second fluid714 (e.g., oil, etc.) that is immiscible with theaqueous fluid712 in thereservoir704 to createdroplets720 of theaqueous fluid712 flowing into thereservoir704. At thejunction706 where theaqueous fluid712 and thesecond fluid714 meet, droplets can form based on factors such as the hydrodynamic forces at thejunction706, relative flow rates of the twofluids712,714, fluid properties, and certain geometric parameters (e.g., Δh, etc.) of thechannel structure700. A plurality of droplets can be collected in thereservoir704 by continuously injecting theaqueous fluid712 from thechannel segment702 at thejunction706.
• A discrete droplet generated may comprise one or more particles of the plurality ofparticles716. As described elsewhere herein, a particle may be any particle, such as a bead, cell bead, gel bead, biological particle, macromolecular constituents of biological particle, or other particles. Alternatively, a discrete droplet generated may not include any particles.
• In some instances, theaqueous fluid712 can have a substantially uniform concentration or frequency ofparticles716. As described elsewhere herein (e.g., with reference toFIG. 4), the particles716 (e.g., beads) can be introduced into thechannel segment702 from a separate channel (not shown inFIG. 7). The frequency ofparticles716 in thechannel segment702 may be controlled by controlling the frequency in which theparticles716 are introduced into thechannel segment702 and/or the relative flow rates of the fluids in thechannel segment702 and the separate channel. In some instances, theparticles716 can be introduced into thechannel segment702 from a plurality of different channels, and the frequency controlled accordingly. In some instances, different particles may be introduced via separate channels. For example, a first separate channel can introduce beads and a second separate channel can introduce biological particles into thechannel segment702. The first separate channel introducing the beads may be upstream or downstream of the second separate channel introducing the biological particles.
• In some instances, thesecond fluid714 may not be subjected to and/or directed to any flow in or out of thereservoir704. For example, thesecond fluid714 may be substantially stationary in thereservoir704. In some instances, thesecond fluid714 may be subjected to flow within thereservoir704, but not in or out of thereservoir704, such as via application of pressure to thereservoir704 and/or as affected by the incoming flow of theaqueous fluid712 at thejunction706. Alternatively, thesecond fluid714 may be subjected and/or directed to flow in or out of thereservoir704. For example, thereservoir704 can be a channel directing thesecond fluid714 from upstream to downstream, transporting the generated droplets.
• Thechannel structure700 at or near thejunction706 may have certain geometric features that at least partly determine the sizes and/or shapes of the droplets formed by thechannel structure700. Thechannel segment702 can have a first cross-section height, h₁, and thereservoir704 can have a second cross-section height, h₂. The first cross-section height, h₁, and the second cross-section height, h₂, may be different, such that at thejunction706, there is a height difference of Δh. The second cross-section height, h₂, may be greater than the first cross-section height, h₁. In some instances, the reservoir may thereafter gradually increase in cross-section height, for example, the more distant it is from thejunction706. In some instances, the cross-section height of the reservoir may increase in accordance with expansion angle, β, at or near thejunction706. The height difference, Δh, and/or expansion angle, β, can allow the tongue (portion of theaqueous fluid712 leavingchannel segment702 atjunction706 and entering thereservoir704 before droplet formation) to increase in depth and facilitate decrease in curvature of the intermediately formed droplet. For example, droplet size may decrease with increasing height difference and/or increasing expansion angle.
• The height difference, Δh, can be at least about 1 μm. Alternatively, the height difference can be at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500 μm or more. Alternatively, the height difference can be at most about 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 45, 40, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 μm or less. In some instances, the expansion angle, β, may be between a range of from about 0.5° to about 4°, from about 0.1° to about 10°, or from about 0° to about 90°. For example, the expansion angle can be at least about 0.01°, 0.1°, 0.2°, 0.3°, 0.4°, 0.5°, 0.6°, 0.7°, 0.8°, 0.9°, 1°, 2°, 3°, 4°, 5°, 6°, 7°, 8°, 9°, 10°, 15°, 20°, 25°, 30°, 35°, 40°, 45°, 50°, 55°, 60°, 65°, 70°, 75°, 80°, 85°, or higher. In some instances, the expansion angle can be at most about 89°, 88°, 87°, 86°, 85°, 84°, 83°, 82°, 81°, 80°, 75°, 70°, 65°, 60°, 55°, 50°, 45°, 40°, 35°, 30°, 25°, 20°, 15°, 10°, 9°, 8°, 7°, 6°, 5°, 4°, 3°, 2°, 1°, 0.1°, 0.01°, or less.
• In some instances, the flow rate of theaqueous fluid712 entering thejunction706 can be between about 0.04 microliters (μL)/minute (min) and about 40 μL/min. In some instances, the flow rate of theaqueous fluid712 entering thejunction706 can be between about 0.01 microliters (μL)/minute (min) and about 100 μL/min. Alternatively, the flow rate of theaqueous fluid712 entering thejunction706 can be less than about 0.01 μL/min. Alternatively, the flow rate of theaqueous fluid712 entering thejunction706 can be greater than about 40 μL/min, such as 45 μL/min, 50 μL/min, 55 μL/min, 60 μL/min, 65 μL/min, 70 μL/min, 75 μL/min, 80 μL/min, 85 μL/min, 90 μL/min, 95 μL/min, 100 μL/min, 110 μL/min, 120 μL/min, 130 μL/min, 140 μL/min, 150 μL/min, or greater. At lower flow rates, such as flow rates of about less than or equal to 10 microliters/minute, the droplet radius may not be dependent on the flow rate of theaqueous fluid712 entering thejunction706. Thesecond fluid714 may be stationary, or substantially stationary, in thereservoir704. Alternatively, thesecond fluid714 may be flowing, such as at the above flow rates described for theaqueous fluid712.
• In some instances, at least about 50% of the droplets generated can have uniform size. In some instances, at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater of the droplets generated can have uniform size. Alternatively, less than about 50% of the droplets generated can have uniform size.
• WhileFIGS. 7A and 7B illustrate the height difference, Δh, being abrupt at the junction706 (e.g., a step increase), the height difference may increase gradually (e.g., from about 0 μm to a maximum height difference). Alternatively, the height difference may decrease gradually (e.g., taper) from a maximum height difference. A gradual increase or decrease in height difference, as used herein, may refer to a continuous incremental increase or decrease in height difference, wherein an angle between any one differential segment of a height profile and an immediately adjacent differential segment of the height profile is greater than 90°. For example, at thejunction706, a bottom wall of the channel and a bottom wall of the reservoir can meet at an angle greater than 90°. Alternatively or in addition, a top wall (e.g., ceiling) of the channel and a top wall (e.g., ceiling) of the reservoir can meet an angle greater than 90°. A gradual increase or decrease may be linear or non-linear (e.g., exponential, sinusoidal, etc.). Alternatively or in addition, the height difference may variably increase and/or decrease linearly or non-linearly. WhileFIGS. 7A and 7B illustrate the expanding reservoir cross-section height as linear (e.g., constant expansion angle, β), the cross-section height may expand non-linearly. For example, the reservoir may be defined at least partially by a dome-like (e.g., hemispherical) shape having variable expansion angles. The cross-section height may expand in any shape.
• The channel networks, e.g., as described above or elsewhere herein, can be fluidly coupled to appropriate fluidic components. For example, the inlet channel segments are fluidly coupled to appropriate sources of the materials they are to deliver to a channel junction. These sources may include any of a variety of different fluidic components, from simple reservoirs defined in or connected to a body structure of a microfluidic device, to fluid conduits that deliver fluids from off-device sources, manifolds, fluid flow units (e.g., actuators, pumps, compressors) or the like. Likewise, the outlet channel segment (e.g.,channel segment208,reservoir604, etc.) may be fluidly coupled to a receiving vessel or conduit for the partitioned cells for subsequent processing. Again, this may be a reservoir defined in the body of a microfluidic device, or it may be a fluidic conduit for delivering the partitioned cells to a subsequent process operation, instrument or component.
• The methods and systems described herein may be used to greatly increase the efficiency of single cell applications and/or other applications receiving droplet-based input. For example, following the sorting of occupied cells and/or appropriately-sized cells, subsequent operations that can be performed can include generation of amplification products, purification (e.g., via solid phase reversible immobilization (SPRI)), further processing (e.g., shearing, ligation of functional sequences, and subsequent amplification (e.g., via PCR)). These operations may occur in bulk (e.g., outside the partition). In the case where a partition is a droplet in an emulsion, the emulsion can be broken and the contents of the droplet pooled for additional operations. Additional reagents that may be co-partitioned along with the barcode bearing bead may include oligonucleotides to block ribosomal RNA (rRNA) and nucleases to digest genomic DNA from cells. Alternatively, rRNA removal agents may be applied during additional processing operations. The configuration of the constructs generated by such a method can help minimize (or avoid) sequencing of the poly-T sequence during sequencing and/or sequence the 5′ end of a polynucleotide sequence. The amplification products, for example, first amplification products and/or second amplification products, may be subject to sequencing for sequence analysis. In some cases, amplification may be performed using the Partial Hairpin Amplification for Sequencing (PHASE) method.
• A variety of applications require the evaluation of the presence and quantification of different biological particle or organism types within a population of biological particles, including, for example, microbiome analysis and characterization, environmental testing, food safety testing, epidemiological analysis, e.g., in tracing contamination or the like.
Computer Systems
• The present disclosure provides computer systems that are programmed to implement methods of the disclosure.FIG. 14 shows acomputer system1401 that is programmed or otherwise configured to (i) control a microfluidics system (e.g., fluid flow), (ii) sort occupied droplets from unoccupied droplets, (iii) polymerize droplets, (iv) perform sequencing applications, (v) generate and maintain sets of molecules or molecules combinations, etc. The computer system1201 can regulate various aspects of the present disclosure, such as, for example, regulating fluid flow rate in one or more channels in a microfluidic structure, regulating polymerization application units, regulating library generation, etc. Thecomputer system1401 can be an electronic device of a user or a computer system that is remotely located with respect to the electronic device. The electronic device can be a mobile electronic device.
• Thecomputer system1401 includes a central processing unit (CPU, also “processor” and “computer processor” herein)1405, which can be a single core or multi core processor, or a plurality of processors for parallel processing. Thecomputer system1401 also includes memory or memory location1410 (e.g., random-access memory, read-only memory, flash memory), electronic storage unit1415 (e.g., hard disk), communication interface1420 (e.g., network adapter) for communicating with one or more other systems, andperipheral devices1425, such as cache, other memory, data storage and/or electronic display adapters. Thememory1410,storage unit1415,interface1420 andperipheral devices1425 are in communication with theCPU1405 through a communication bus (solid lines), such as a motherboard. Thestorage unit1415 can be a data storage unit (or data repository) for storing data. Thecomputer system1401 can be operatively coupled to a computer network (“network”)1430 with the aid of thecommunication interface1420. Thenetwork1430 can be the Internet, an internet and/or extranet, or an intranet and/or extranet that is in communication with the Internet. Thenetwork1430 in some cases is a telecommunication and/or data network. Thenetwork1430 can include one or more computer servers, which can enable distributed computing, such as cloud computing. Thenetwork1430, in some cases with the aid of thecomputer system1401, can implement a peer-to-peer network, which may enable devices coupled to thecomputer system1401 to behave as a client or a server.
• TheCPU1405 can execute a sequence of machine-readable instructions, which can be embodied in a program or software. The instructions may be stored in a memory location, such as thememory1410. The instructions can be directed to theCPU1405, which can subsequently program or otherwise configure theCPU1405 to implement methods of the present disclosure. Examples of operations performed by theCPU1405 can include fetch, decode, execute, and writeback.
• TheCPU1405 can be part of a circuit, such as an integrated circuit. One or more other components of thesystem1401 can be included in the circuit. In some cases, the circuit is an application specific integrated circuit (ASIC).
• Thestorage unit1415 can store files, such as drivers, libraries and saved programs. Thestorage unit1415 can store user data, e.g., user preferences and user programs. Thecomputer system1401 in some cases can include one or more additional data storage units that are external to thecomputer system1401, such as located on a remote server that is in communication with thecomputer system1401 through an intranet or the Internet.
• Thecomputer system1401 can communicate with one or more remote computer systems through thenetwork1430. For instance, thecomputer system1401 can communicate with a remote computer system of a user (e.g., operator). Examples of remote computer systems include personal computers (e.g., portable PC), slate or tablet PC's (e.g., Apple® iPad, Samsung® Galaxy Tab), telephones, Smart phones (e.g., Apple® iPhone, Android-enabled device, Blackberry®), or personal digital assistants. The user can access thecomputer system1401 via thenetwork1430.
• Methods as described herein can be implemented by way of machine (e.g., computer processor) executable code stored on an electronic storage location of thecomputer system1401, such as, for example, on thememory1410 orelectronic storage unit1415. The machine executable or machine readable code can be provided in the form of software. During use, the code can be executed by theprocessor1405. In some cases, the code can be retrieved from thestorage unit1415 and stored on thememory1410 for ready access by the processor1205. In some situations, theelectronic storage unit1415 can be precluded, and machine-executable instructions are stored onmemory1410.
• The code can be pre-compiled and configured for use with a machine having a processor adapted to execute the code, or can be compiled during runtime. The code can be supplied in a programming language that can be selected to enable the code to execute in a pre-compiled or as-compiled fashion.
• Aspects of the systems and methods provided herein, such as thecomputer system1401, can be embodied in programming. Various aspects of the technology may be thought of as “products” or “articles of manufacture” typically in the form of machine (or processor) executable code and/or associated data that is carried on or embodied in a type of machine readable medium. Machine-executable code can be stored on an electronic storage unit, such as memory (e.g., read-only memory, random-access memory, flash memory) or a hard disk. “Storage” type media can include any or all of the tangible memory of the computers, processors or the like, or associated modules thereof, such as various semiconductor memories, tape drives, disk drives and the like, which may provide non-transitory storage at any time for the software programming. All or portions of the software may at times be communicated through the Internet or various other telecommunication networks. Such communications, for example, may enable loading of the software from one computer or processor into another, for example, from a management server or host computer into the computer platform of an application server. Thus, another type of media that may bear the software elements includes optical, electrical and electromagnetic waves, such as used across physical interfaces between local devices, through wired and optical landline networks and over various air-links. The physical elements that carry such waves, such as wired or wireless links, optical links or the like, also may be considered as media bearing the software. As used herein, unless restricted to non-transitory, tangible “storage” media, terms such as computer or machine “readable medium” refer to any medium that participates in providing instructions to a processor for execution.
• Hence, a machine readable medium, such as computer-executable code, may take many forms, including but not limited to, a tangible storage medium, a carrier wave medium or physical transmission medium. Non-volatile storage media include, for example, optical or magnetic disks, such as any of the storage devices in any computer(s) or the like, such as may be used to implement the databases, etc. shown in the drawings. Volatile storage media include dynamic memory, such as main memory of such a computer platform. Tangible transmission media include coaxial cables; copper wire and fiber optics, including the wires that comprise a bus within a computer system. Carrier-wave transmission media may take the form of electric or electromagnetic signals, or acoustic or light waves such as those generated during radio frequency (RF) and infrared (IR) data communications. Common forms of computer-readable media therefore include for example: a floppy disk, a flexible disk, hard disk, magnetic tape, any other magnetic medium, a CD-ROM, DVD or DVD-ROM, any other optical medium, punch cards paper tape, any other physical storage medium with patterns of holes, a RAM, a ROM, a PROM and EPROM, a FLASH-EPROM, any other memory chip or cartridge, a carrier wave transporting data or instructions, cables or links transporting such a carrier wave, or any other medium from which a computer may read programming code and/or data. Many of these forms of computer readable media may be involved in carrying one or more sequences of one or more instructions to a processor for execution.
• Thecomputer system1401 can include or be in communication with anelectronic display1435 that comprises a user interface (UI)1440 for providing, for example, results of sequencing analysis, the identity of molecules in a library, etc. Examples of UIs include, without limitation, a graphical user interface (GUI) and web-based user interface.
• Methods and systems of the present disclosure can be implemented by way of one or more algorithms. An algorithm can be implemented by way of software upon execution by thecentral processing unit1405. The algorithm can, for example, perform sequencing, identify molecules in a library, etc.
EXAMPLESExample 1. Evaluating B-Cell Affinity
• Gel beads are provided which each comprise an oligonucleotide and an attached streptavidin protein. The gel beads are randomly partitioned into wells of a first plate. Each well of the first plate contains a known polypeptide molecule attached to a biotin moiety and a known nucleic acid molecule comprising a unique barcode sequence. The nucleic acid molecules in each well of the first plate are ligated to the oligonucleotide of the gel beads. The polypeptide molecules in each well of the first plate are attached to the streptavidin proteins on the gel beads via the biotin moiety. The gel beads are then released from the wells and pooled.
• Following release, the gel beads are randomly partitioned into wells of a second plate. Each well of the second plate contains a known polypeptide sequence and a known nucleic acid molecule comprising a unique barcode sequence. The nucleic acids in each well of the second plate are ligated to the nucleic acid molecules linked to the gel beads. The polypeptide molecules in each well of the second plate are attached to the polypeptide molecules linked to the gel beads via peptide synthesis techniques. The gel beads are then released from the wells and pooled.
• Having generated gel beads containing a diverse library of nucleic acid barcode sequences and polypeptide molecules, the gel beads can be used to evaluate B-cell affinity.FIG. 11 shows a process for evaluating B-cell affinity using gel beads comprising a library of nucleic acid barcode sequences and polypeptide molecules.Gel beads1110,1111,1112, and1113, each comprising a unique barcode molecule and unique polypeptide molecule, are incubated with B-cells obtained from a subject1101,1102,1103,1104, and1105. A portion of the B-cells contain B-cell receptors with affinity for polypeptide molecules attached to the gel beads. B-cells with affinity for the polypeptide molecules adhere to the gel beads, formingcomplexes1121,1122,1123, and1124. Unbound B-cells (not shown inFIG. 11) are removed. Complexes are then partitioned intodroplets1131,1132,1133, and1134, with each droplet containing a single complex and reagents suitable for performing reverse transcription and nucleic acid barcoding. Once in the droplets, the nucleic acid molecules comprising the unique barcode sequences are released from the gel beads. The B-cells are lysed and reverse transcription is performed using a poly-T primer, thereby generating complementary DNA. The nucleic acid molecule is used to attach a unique barcode sequence to the complementary DNA in each droplet. Barcoded complementary DNA is released from the droplet, amplified, and subjected to nucleic acid sequencing to generate sequences corresponding to the DNA of the B-cell receptor. The sequences contain unique barcode sequences, which serve to identify the sequence with an individual gel bead, and therefore an individual polypeptide molecule. In this way, DNA sequences of B-cell receptors from one or more B-cells are individually identified together with their affinity for a given polypeptide.
Example 2. Screening of Drug Combinations for Anti-Cancer Efficacy
• Gel beads are generated which each comprise a nucleic acid molecule comprising a unique nucleic acid barcode sequence. Each gel bead also comprises a drug combination which can be identified by the nucleic acid barcode sequence. The drugs are attached to the gel beads via an amide bond. In total the gel beads comprise 1,000 different unique drug combinations, each associated with a nucleic acid barcode sequence.
• Cancer cells are separated into droplets along with the gel beads such that each droplet contains at most one cell and one gel bead. The compounds are released from the gel beads via cleavage of the amide bonds and allowed to interact with the cells in the droplets for a period of time sufficient to alter gene expression in the cells. The cells are then lysed and the nucleic acid molecules released from the gel beads. Reverse transcription is performed to generate complementary DNA from messenger RNA in each cell. The nucleic acid molecules are used to generate barcoded complementary DNA. The barcoded complementary DNA is released from the droplets and subjected to nucleic acid sequencing to generate sequences corresponding to the messenger RNA from each cell. The sequences comprise the nucleic acid barcode sequences, thereby identifying the sequences with an individual cell and also with a specific drug combination. Expression of pro-apoptotic genes in each single cell is determined from the sequences, and this expression is correlated with the drug combination applied to the cell. One drug combination is identified as the most effective in increasing expression of pro-apoptotic genes in the cancer cells.
• Devices, systems, compositions and methods of the present disclosure may be used for various applications, such as, for example, processing a single analyte (e.g., RNA, DNA, or protein) or multiple analytes (e.g., DNA and RNA, DNA and protein, RNA and protein, or RNA, DNA and protein) from a single cell. For example, a biological particle (e.g., a cell or cell bead) is partitioned in a partition (e.g., droplet), and multiple analytes from the biological particle are processed for subsequent processing. The multiple analytes may be from the single cell. This may enable, for example, simultaneous proteomic, transcriptomic and genomic analysis of the cell.
• While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the invention be limited by the specific examples provided within the specification. While the invention has been described with reference to the aforementioned specification, the descriptions and illustrations of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. Furthermore, it shall be understood that all aspects of the invention are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is therefore contemplated that the invention shall also cover any such alternatives, modifications, variations or equivalents. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims (37)

1. A method for generating a plurality of molecules, comprising:

(a) providing a plurality of supports; and

(b) combinatorially generating a plurality of molecules coupled to and/or comprised in each of said plurality of supports, wherein a support of said plurality of supports comprises a first set of molecules and a second set of molecules of said plurality of molecules, which first set of molecules and second set of molecules are of different types.

2. The method ofclaim 1, wherein said first set of molecules comprises deoxyribonucleic acid (DNA) molecules and said second set of molecules comprises molecules selected from the group consisting of (i) ribonucleic acid (RNA) molecules, (ii) peptide molecules, (iii) chemical compounds each having a molecular weight less than 900 Daltons, and (iv) molecules that are not DNA and RNA.

3. (canceled)

4. The method ofclaim 1, wherein said first set of molecules comprises ribonucleic acid (RNA) molecules and said second set of molecules comprises molecules selected from the group consisting of (i) peptide molecules, (ii) chemical compounds each having a molecular weight less than 900 Daltons, and (iii) molecules that are not DNA and RNA.

5.-7. (canceled)

8. The method ofclaim 1, wherein said first set of molecules comprises one or more nucleic acid barcode sequences.

9. The method ofclaim 1, wherein said plurality of supports is a plurality of beads.

10. The method ofclaim 1, wherein molecules of said first set of molecules have sequences that encode molecules of said second set of molecules.

11. (canceled)

12. The method ofclaim 1, wherein at least a subset of said plurality of molecules is combinatorially generated by sequentially coupling one or more molecules to said plurality of supports or sequentially capturing one or more molecules within said plurality of supports.

13. The method ofclaim 12, wherein said at least said subset of said plurality of molecules comprises a first molecule comprising a first segment and a second molecule comprising a second segment, and wherein said combinatorially generating comprises coupling said first molecule to a molecule coupled to a support of said plurality of supports and coupling said second molecule to said first molecule.

14.-16. (canceled)

17. The method ofclaim 13, further comprising coupling a third molecule comprising a third segment to said second molecule, wherein said third segment is different from said first segment or said second segment.

18.-21. (canceled)

22. The method ofclaim 12, wherein said coupling comprises partitioning said at least said subset of said plurality of molecules in separate partitions, and coupling said one or more molecules to each of said plurality of supports in said separate partitions.

23.-25. (canceled)

26. The method ofclaim 12, wherein said plurality of supports is a plurality of beads, and wherein said capturing comprises encapsulating said one or more molecules in said plurality of beads.

27. The method ofclaim 12, wherein said capturing comprises partitioning said at least said subset of said plurality of molecules in separate partitions, and capturing said one or more molecules in each of said plurality of supports in said separate partitions.

28.-29. (canceled)

30. A method for generating a plurality of molecules, comprising:

(a) providing a plurality of supports in a first plurality of partitions comprising a first set of molecules and a second set of molecules, which first set of molecules and second set of molecules are of different types;

(b) coupling said first set of molecules and said second set of molecules to said plurality of supports;

(c) providing said plurality of supports in a second plurality of partitions comprising a third set of molecules and a fourth set of molecules which third set of molecules and fourth set of molecules are of different types; and

(d) coupling said third set of molecules and said fourth set of molecules to said plurality of supports.

31. The method ofclaim 30, wherein (i) said first set of molecules and said third set of molecules comprise deoxyribonucleic acid (DNA) molecules and (ii) said second set of molecules and said fourth set of molecules comprise ribonucleic acid (RNA) molecules.

32. The method ofclaim 30, wherein (i) said first set of molecules and said third set of molecules comprise deoxyribonucleic acid (DNA) molecules and (ii) said second set of molecules and said fourth set of molecules comprise molecules selected from the group consisting of (A) peptide molecules, (B) chemical compounds each having a molecular weight less than 900 Daltons, and (C) molecules that are not DNA and RNA.

33. The method ofclaim 30, wherein (i) said first set of molecules and said third set of molecules comprise ribonucleic acid (RNA) molecules and (ii) said second set of molecules and said fourth set of molecules comprise molecules selected from the group consisting of (A) peptide molecules, (B) chemical compounds each having a molecular weight less than 900 Daltons, and (C) molecules that are not DNA and RNA.

34.-36. (canceled)

37. The method ofclaim 30, wherein (d) comprises coupling said third set of molecules to said first set of molecules or to said plurality of supports.

38. (canceled)

39. The method ofclaim 30, wherein (d) comprises coupling said fourth set of molecules to said second set of molecules or to said plurality of supports.

40. (canceled)

41. The method ofclaim 30, wherein said first set of molecules and/or said third set of molecules comprises one or more nucleic acid barcode sequences.

42. The method ofclaim 30, wherein said plurality of supports is a plurality of beads.

43. The method ofclaim 30, wherein said first set of molecules and said third set of molecules positively identify said second set of molecules and said fourth set of molecules.

44. The method ofclaim 30, further comprising (e) providing said plurality of supports in a third plurality of partitions comprising a fifth set of molecules and a sixth set of molecules which fifth set of molecules and sixth second set of molecules are of different types; and (f) coupling said fifth set of molecules and said sixth set of molecules to said plurality of supports.

45. (canceled)

46. The method ofclaim 30, wherein said first plurality of partitions is a plurality of wells or a plurality of droplets.

47. (canceled)

48. The method ofclaim 30, wherein said second plurality of partitions is a plurality of wells or a plurality of droplets.

49.-53. (canceled)

Images